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ELECTROPHYSIOLOGICAL AND NEUROPSYCHOLOGICAL 
MEASURES IN PATIENTS WITH SCHIZOPHRENIA AND THEIR 
UNAFFECTED BIOLOGICAL SIBLINGS: A FAMILY STUDY 
ABSTRACT: 
Background: Various neuropsychological domains and P300 auditory 
event related potentials exhibit abnormalities in patients with schizophrenia and 
their first-degree relatives. The aim of the study is to compare the cognitive and 
P300 measurements in patients with schizophrenia, their unaffected biological 
siblings and normal controls. Also, to find the correlation between the clinical 
variables in patients with schizophrenia and P300 event related potentials and 
neuropsychological test.  
Methods: 30 patients with paranoid schizophrenia according to ICD-10, 
30 unaffected biological siblings of patients with schizophrenia and 30 normal 
controls were able to complete all neuropsychological test and P300 event 
related potential assessments. All participants were administered SCAN and the 
patients were also evaluated regarding the symptom severity.  
Results: Both patients with schizophrenia and the unaffected biological 
siblings of patients with schizophrenia showed lower P300 amplitude and 
longer P300 latency when compared with the normal controls. When compared 
between them, patient and sibling groups showed a statistical difference in P300 
event related potentials. The three groups showed statistically significant 
differences in Digit vigilance test, Visual 2-back test, Controlled oral word 
association test, Animal names test and Stroop test. PANSS total score and 
psychopathology scores were having a statistically significant correlation with 
the P300 event related potential and neuropsychological tests. 
Conclusion: The patients with schizophrenia and the unaffected 
biological siblings of patients with schizophrenia showed abnormalities in P300 
event related potentials and neuropsychological test. These tests were also 
correlated well with the illness characteristics of patients with schizophrenia. 
Keywords: Schizophrenia, Siblings, P300, Neuropsychological tests, PANSS. 
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INTRODUCTION 
Schizophrenia is a chronic, heterogeneous, severe mental illness with 
impairments in spectrum of psychological and social functions. The exact aetiology of 
schizophrenia is not known. Like other psychiatric disorders, bio-psycho-social model 
have been implicated for the causation of schizophrenia (1).  
Even though the mode of inheritance in schizophrenia is complex and 
primarily non-mendelian, it is well established that the schizophrenia has a high 
heritability (2). But the complex phenotype of this disorder makes it difficult for 
finding out the genes involved in the illness process. Because of this, till date, various 
genetic loci been proposed to be associated with schizophrenia but none of them 
proved to be causative (3). Endophenotypes, described as internal phenotypes, are 
quantifiable characters which are product of fewer genes when compared to 
phenotypes and this has the potential to simplify the genetic studies in schizophrenia 
(4-5). Various measures such as biochemical, neurophysiological, neuroanatomical, 
neuroimaging, neuroendocrine and neurocognitive methods are being used as feasible 
methods for endophenotype analysis (6). 
The scalp – recorded event related potential (ERP) has been extensively used 
for the assessment of information processing in the brain (7). When compared to other 
imaging methods live MRI, ERP technique has an excellent temporal resolution and 
this advantage can be made use for studying rapid cognitive processes accurately. In 
recent years, this electrophysiological measure is used for clinical application such as 
for the evaluation of cognitive dysfunctions in various psychiatric disorders especially 
schizophrenia (8). 
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The most important and well researched component of auditory event related 
potential that shows abnormality in is the P300 (9). P300 is correlated with 
information processing in the brain and considered as an index of the same. In most of 
the studies, P300 is elicited by oddball paradigm. In the oddball paradigm, an odd 
stimulus is inserted in between a regularly occurring stimulus and the person taking 
the test responds for the odd stimulus while not the regular stimulus. Various 
endogenous cognitive processes like attention and working memory are correlated 
well with P300 and taken as their index of measure (10). 
Since its first report in 1972, various studies have shown that various event 
related potential abnormalities manifest in persons suffering from schizophrenia, 
namely the reduced P300 amplitude. Similar results are seen in studies conducted on 
the first degree relatives with schizophrenia probands. Hence, event related potential 
abnormalities are considered as the biological vulnerability marker of  
schizophrenia (11).  
The cognitive defects in schizophrenia has been represented in eight different 
domains namely processing speed, attention/vigilance, working memory, verbal and 
visual learning/memory, reasoning and problem solving, verbal comprehension and 
social cognition (12). Moreover, it is observed that these deficits are also found to be 
present in unaffected relatives and twins of schizophrenic patients. Research suggests 
that the cognitive deficits have a strong genetic linkage, tends to run in families and 
predispose the unaffected first degree relatives of patients with schizophrenia to 
develop the disorder in future (13).  
Cognitive impairments and event related potential changes are established 
endophenotype markers in schizophrenia. First-degree relatives of schizophrenic 
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patients are having a high risk for the disorder and they show evidence of deficits in 
endophenotype markers well before the onset of illness. Hence, early assessment of 
high risk persons for various endophenotype abnormalities may lead to early 
identification, regular follow-up, acute management of illness and prevention of 
future illness (6). 
Studies on schizophrenia in which the electrophysiological and 
neurophysiological variables measured in combination in persons with schizophrenia 
and their unaffected siblings are few. Hence the purpose of this current study is to 
assess these two variables, event related potentials and neuropsychological 
performance, in combination in patients and their unaffected biological siblings and to 
compare between and with normal controls. 
This study’s hypothesis is that the event related potential and 
neuropsychological measures would show a continuum between the persons suffering 
with schizophrenia and their unaffected biological siblings with most significant 
abnormalities in patients followed by siblings and the normal controls. This may also 
throw light on the heritability of the neuropsychological and electrophysiological 
measures among siblings of patients with schizophrenia. 
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REVIEW OF LITERATURE 
The review of literature is dealt in three sections. Section A deals with the 
studies relating to the intermediate endophenotypes in genetic studies of 
schizophrenia. Section B deals with the studies examining the electrophysiological 
measures in patients suffering with schizophrenia and their siblings and section C 
deals with the cognitive functions and neuropsychological test measures in 
schizophrenic patients and their siblings. 
SECTION (A): 
Now a days, the genes for simple Mendelian disorders could be identified and 
characterized easily but it is not the case with the psychiatric disorders (14). This is 
because the psychiatric disorders are not produced by the defect in single gene but by 
the influence of various genes from different foci, interacting among themselves and 
with the environment (epigenetics) (15). To circumvent this problem of identifying 
the susceptibility genes involved in complex disorders, the trait like variables 
associated with the complex psychiatric disorders can be taken phenotypes for the 
genetic studies. The clinical features of the psychiatric illnesses are heterogeneous and 
overlap with one another and hence finding the genetic basis for the clinical profile is 
very difficult and not prudent. This has rose the interest in finding the traits that 
directly index the underlying pathology and which are more closed to the genes 
involved in their manifestation (16). Also, these traits are seen not only in persons 
with schizophrenia but in their relatives also. Some relatives of the patients carry the 
susceptible genes in them but not manifesting the disorder. These relatives may show 
abnormalities in the brain structure and functioning which are not attributed to the 
illness but rather to the effects of the susceptible genes on the brain in the absence of 
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the disorder. These traits which are intermediate between the genotype and phenotype 
are called the intermediate phenotypes or endophenotypes (6). 
SECTION (A) I: The concept of endophenotype 
Endophenotypes are described as “internal phenotypes discoverable by 
microscopic examination or biochemical test but is not seen without an aided eye”. 
This term was first used by John et al. and Lewis et al. in their research paper which 
was published in the year 1966 (17). Hence the study of endophenotypes will be 
helpful in identifying the culprit genes readily in the polygenic systems offering 
vulnerability to disorders. 
Many methods have been described for the study of endophenotypes in 
literature. Most important and most studied are neurochemical (18), 
neurophysiological (16), neuroendocrinological (19), neuroanatomical, cognitive (20) 
and neuroimaging (21). Endophenotypes are also called by various other names like 
“intermediate phenotype”, “biological marker”, “subclinical trait” and “vulnerability 
marker” (5).  
Gottesman et al. gave the criteria for particular methods to be called an 
endophenotype (22). The method/test must satisfy the following criteria to be taken 
up as an endophenotype: 
1. Associated with illness in the population. 
2. Heritable. 
3. State – independent. 
4. Co – segregate within families  
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5. Found in the affected family members and also in the non – affected family 
members, the rate being higher in comparison with the general population. 
The search for the candidate endophenotype have been described well in the 
literature for many of the psychiatric illnesses including schizophrenia, mood 
disorders, Alzheimer’s disease, attention deficit hyperactivity disorder and 
personality disorders.  
Endophenotypes are helpful in finding the genes which are related to the 
biological processes that are taking place internally which is manifesting externally as 
the phenotypes of schizophrenia (23). Endophenotype mapping of susceptibility 
genes for psychiatric disorders may help in identifying the specific domains of brain 
function, influenced by relevant risk gene variants of disorders (24). They help us to 
find out single or multiple genes are involved in a particular disorder and how they 
interact to produce the particular phenotype. Biology of the neural circuits underling a 
particular symptom can be studied using the endophenotype (25). Endophenotypes 
could inform the evolution of psychiatric nosology. They help in classifying patients 
on the basis of similar biological deficits into homogenous bio-cognitive subtypes 
across diagnostic categories (26). 
Various endophenotypes that are observed in schizophrenia that have fitting 
criteria for an endophenotype have been proposed. These are eye tracking 
abnormalities, electrophysiological markers like event related potentials measuring 
P300 amplitude, neurochemical abnormalities and positive and negative symptom 
scores. Now, neuroimaging endophenotypes have also been studied. 
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SECTION (A) II: Electrophysiological Endophenotypes 
In early 1970s, electrophysiological measures were first used to assess and 
investigate the information processing deficits in schizophrenia (27). This led to 
recognition of various abnormalities in information processing not only in patients but 
also in the first-degree relatives (28). The most studied electrophysiological processes 
are event-related potentials and startle response.  
Event-related potential studies were mostly done using the auditory oddball 
paradigm but some studies were also done using the visual stimuli evoked event-
related potentials (29). In all these experiments, the primary outcomes were the 
amplitude and latency of the specific wavelength that was studied. 
Studies involving the P50 waveform, also called as the mid latency waveform 
since it occurs 50 milliseconds after the stimulus, have shown that it was reduced to 
the second auditory stimulus in healthy controls showing that sensory gating of the 
irrelevant stimulus in them. But in the case of patients with schizophrenia there were 
impaired gating. At first, it was found that in schizophrenics and nearly 50% of first 
degree relatives of patients with schizophrenia have impaired sensory gating 
mechanism (30). This was used in the linkage studies and was found that it had a 
strong genetic inheritance. This was linked to the markers on the 15q13 in the linkage 
studies.   
Mismatch negativity (MMN) is another important event related potential wave 
which has been studied as an endophenotype (31). No specific attentional process is 
required for the production of MMN as in the case of some other measures like P300. 
The basis of the reduced auditory MMN in the subjects would be due to the 
impairment in the processing of primary auditory stimuli. Turetsky et al. showed that 
 8
the neuroleptics have limited effect on the MMN (32). Magno et al. showed that the 
MMN abnormalities in the patients with schizophrenia were not found at the start of 
the illness but emerged as the illness process proceeded (33). Bruggemann et al. 
observed that the mismatch negativity deficits were found in the high-risk subjects 
(34). The heritability of MMN is not very evident and the overall data regarding the 
heritability is also limited. A twin study by Hall et al. showed that there was 
significant heritability of MMN in the family.    
P300 is the most studied intermediate phenotype in schizophrenia and many 
features of P300 satisfy the criteria for an ideal phenotype. Many studies involving the 
P300 had used the auditory oddball paradigm for conducting the experiment (35). 
P300 reflects many cognitive processes which include attention, working memory and 
context updating (36). P300 had been distinguished into two components, namely the 
P3a and P3b, by some studies. Most consistent finding in many of the studies 
involving the P300 were the reduced P300 amplitude and to a lesser extent, the 
increased latency in schizophrenia (37). Several meta-analyses have reported the same 
findings. Reduced P300 amplitude has also been seen in the persons with high risk of 
schizophrenia and also in first degree relatives of patients with schizophrenia (38). 
Another important finding regarding the reduced amplitude of P300 in patients with 
schizophrenia is that it does not change with the start of the antipsychotic medication. 
This is seen as a proof that P300 is indeed a trait marker of schizophrenia. Family 
studies involving the P300 component suggests that it has a very strong genetic 
component (39). Many twin studies and other genetic studies have shown that there is 
a substantial correlation between the P300 amplitude and genetic risk of 
schizophrenia (10). Association studies have come up with positive findings linking 
P300 and several candidate genes like the D3 dopamine receptor and COMT (40). The 
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major issue with the P300 amplitude is that it is not specific to schizophrenia but is 
also impaired in various other disorders like the dementia, depression, alcoholism and 
bipolar affective disorder.  
SECTION (A) III: Neuropsychological endophenotypes 
Egan et al. expressed that the importance of schizophrenia endophenotypes is 
"to inform genetic studies of psychiatric disorders is never as productive and exciting 
as in neuropsychological studies". This is due to the fact that the cognitive deficits in 
schizophrenia are trait like core features of this illness and these deficits play an 
important role in clinical and functional outcome (41). It is suggested that there may 
be several endophenotypes derived from neuropsychological test data. Results from 
twin and family studies by Park et al. and Cannon et al. had observed that visuo-
spatial working memory functions, related to prefrontal neural systems, but also 
verbal working memory functions may be potentially valid endophenotypes that can 
be taken up for the genetic analyses (42). In another study, Egan et al. had observed 
that the relative risk of impairment in siblings of schizophrenia patients was elevated 
not only in verbal learning and memory functions but also in executive functions (41). 
The studies assessing the relative risk of impairments in first-degree relatives of 
patients with schizophrenia had shown that the deficits were present in multiple 
domains of cognitive functions and this suggested that multiple test scores were 
needed to study the genetic linkage analysis (43). 
Executive function is one’s ability to plan, initiate, sequence, monitor and 
inhibit complex goal-directed behaviour. International neuropsychological society 
(INS) defines executive functions as: “cognitive abilities necessary for complex goal 
directed behaviour and adaptation to a range of environmental changes and demands”. 
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Executive functions include the ability to plan and anticipate out comes (cognitive 
flexibility) and to direct attentional resources to meet the demands of non-routine 
events. Many conceptualizations of executive functions also include self-monitoring 
and self-awareness since they are necessary for behavioural flexibility and 
appropriateness (44). 
Executive functions are needed to carry out the day today activities but also to 
plan and execute higher activities which are more goals oriented. Executive skills are 
most important for dealing novel or complex situation. Goldberg et al. referred to the 
loss of meaningful, directed behaviour resulting from the frontal lobe lesions (45). 
Pre-frontal cortex is the seat for the executive functions (46). Executive functions play 
a major role in activities of daily life including the ability to work or attend school, 
functional responsibility in the home or have appropriate social relationships (47). 
Hutton et al. observed that patients with first episode schizophrenia were particularly 
impaired on selected executive function and also had poor verbal memory (48). Joyce 
et al. found that deficits in executive functions play an important role in the prognosis 
of the patient and also they act as the determinants of functional outcome (49). 
SECTION (B): 
The first person to observe that the electrical responses could be evoked from 
the brain was Caton (1895). Hans Berger, in 1929, reported the first recordings of the 
EEG from the scalp of human subjects. He coined the term “electroencephalogram” 
or EEG (50). He measured the electrical activity by placing the electrodes on the scalp 
of the human subjects, then amplifying the signals and recording them as changes in 
the voltage over time. He also showed the relationship between the mental processes 
in the subjects and the EEG signal changes. After this the field of electrophysiology 
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grew fast. Evoked potentials were first observed by Davis in 1939 and showed the 
changes in the EEG associated with a particular sensory stimulus. To improve the 
signal to noise ratio, Dawson in 1954, averaged a number of evoked potentials and 
obtained the desired results. This averaging of the signals helped to eliminate the 
unwanted muscle movement artefacts and showed only the most consistent voltage 
changes in the EEG. This was the starting point of Event-Related Potentials (ERPs). 
The first peak in ERP was discovered by Walter, which was called as the Contingent 
variation or CNV. Sutton (1965) discovered the positive peak in amplitude elicited by 
infrequent stimulus and it was called as P300 (51). 
Before 1950s, there was no standard system for the placement of electrodes on 
the scalp of the human subjects for the measurement of EEG. This led to the 
development of a committee and it produced the international 10-20 placement 
system (52). After this, ERPs are measured using different number of electrodes like 
32, 64, 128 and 256 channels (53).   
SECTION (B) I: Event related potential 
Event related potentials are the positive and negative voltage deflections in the 
voltage of the ongoing electroencephalogram (EEG) signal. This event related 
potentials (ERP) are produced by the activity of brain while it is undergoing a 
cognitive, motor or sensory event (8).  
There are two types of electrical activity generated by the neurons. They are the 
action potentials and post-synaptic potentials and thus they could be the neural basis 
of event related potentials (54). Action potentials are the voltage spikes that are 
generated from the beginning of the axon and they travel towards the terminals. When 
the voltage spike reaches the terminal, they cause the release of the neurotransmitter 
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into the synapse. This release of the neurotransmitters into the cleft causes the 
excitation of the post-synaptic neuron. Post-synaptic potentials are also voltage spikes 
that are produced in the post-synaptic neuron when the neurotransmitters bind to the 
receptors present on the post-synaptic neuron. Among these two potentials, action 
potentials are negligible contribution to the production ERP signal because they last 
about a millisecond, produced at different times and travels fast down the axon. But in 
contrast, post-synaptic potentials occur at fixed locations of the cell membrane and 
present for hundreds of milliseconds. These occurrences of the post-synaptic activity 
in millions of neurons which are spatially aligned produce the signal measurable in 
the scalp after summation. These are mostly done by the pyramidal cells lying in the 
perpendicular direction to the scalp. Thus it is taken for granted that the ERP peaks 
are produced mostly by pyramidal neurons post-synaptic potentials (55).  
In the ongoing EEG, timed triggers are placed which elicit a response in form 
of activity of the brain. These are recorded in the EEG as voltage deflections. These 
recording of the deflections in the EEG activity can be later extracted and measured as 
ERP after filtering and averaging the EEG data. ERPs are extracted from the EEG 
data by averaging a number of epochs which are time locked to a particular event. An 
epoch is the time frame where the response for a particular stimulus occurs in the 
ERP, which can be either stimulus locked or response locked.  
Since the voltage variations evoked by the brain during the activity in response 
to the target stimuli is very small when compared with the ongoing background EEG, 
signal averaging is the most common technique used to extract the signal which is the 
time-locked ERP from the noise which is the background EEG. Signal-to-noise ratio 
is enhanced by the signal averaging technique. Since the background EEG activity 
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randomly varies when the average is taken, its sum becomes zero. The remaining will 
be the non-random, stimulus locked brain activity. 
The advantages and disadvantages of the ERP technique are many. The post-
synaptic potentials, which are waxing and waning, are volume conducted to the scalp. 
From the scalp, these potentials are picked up by the EEG electrodes. The conduction 
delay between the brain activity and its reflection in the EEG signal is below a 
millisecond. Hence, the ERP technique is superior when compared to the 
neuroimaging technique in its temporal resolution as it allows detecting the brain 
activity in millisecond to millisecond basis. But at the same time, ERPs are poor in 
their spatial resolution when compared with the neuroimaging techniques. This 
disadvantage of the ERP can be attributed to the weak conductive capacity of the 
scalp leading to the marked blurring of signal.  
Event related potentials are very much used in the investigations pertaining to 
attention and information processing. As the information processing ability of the 
humans lie in the brain, it is prudent to explore them it in vivo to promote further 
understanding of the cognitive processes. Thus, ERPs provide a platform for the 
research which explores the neuropsychological mechanisms underlying the cognitive 
deficits in schizophrenia.    
SECTION (B) II: Different ERP waveforms 
Pre-pulse inhibition 
The startle response is evoked by the sudden occurrence of an unexpected 
stimulus which could be auditory and this stimulus could be suppressed by another 
stimulus which is presented before it (pre-pulse stimulus) usually occurring 60- 120 
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ms earlier. The importance of this wave pattern is that it reflects the sensorimotor 
gating mechanism (56).   
P50 wave 
The basic mechanism used by the central nervous system to deal with 
numerous external stimuli is filtering or gating the stimuli called the sensory gating. 
When two identical stimuli are given to an individual, the amount of attenuation in the 
neural pathway for the second identical stimulus measures the strength of the sensory 
gating or the inhibitory pathway. Sensory gating is very important for selecting the 
salient stimuli and to ignore the irrelevant, repetitive stimulus. This reduces the 
person’s response to low information stimuli and directs the attention towards the 
high information stimuli (57). P50 is a positive peak which usually occurs between 
the 40 and 75 milliseconds after the presentation of the stimulus.  
N100 
This is the negative deflection that is peaking around 90 – 200 ms after the 
stimulus and it is observed that is produced after an unexpected stimulus. This is 
produced as an orienting response or a “matching process” since in this the presenting 
stimulus is compared with previously given stimulus (58).  
P200 
It is a positive peak that occurs around 100 – 250 ms after the presentation of 
the stimulus. Recent research indicates that this wave form may reflect the sensation 
seeking behaviour of humans (59).  
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N200 
This is the negative wave occurring around 200 ms after the stimulus (60). It 
has 3 components: 
1.  N2a/Mismatch negativity 
Mismatch negativity is a short latency brain event occurring after the 
presentation of an odd stimulus in a series of repetitive standard stimuli. The 
mismatch negativity occurs between 100-220 ms after presentation of the odd 
stimulus. The most important thing that differentiates the mismatch negativity from 
the P300 is that the P300 requires the attention of the subject to consciously process 
the deviant stimulus while it is not required in the case of mismatch negativity. Hence, 
the mismatch negativity is called as the “pre-attentive”. It is thought that it reflects the 
operations of the sensory memory.  
2. N2b 
It is later in latency and occurs when the physical quality of the stimulus is 
changed.  
N2c 
It is elicited when classification of disparate stimulus is required. 
P300 
This is separately dealt in the next section. 
N400 
It is observed in the context of semantic incongruency (61). It is produced 300 
– 600ms after the presentation of the stimulus and it is related inversely to the 
expectancy of completing a sentence with a given word.  
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P600 
It is seen in relation with the language processing. It wave form is usually seen 
in the ERP if the language contains violations to syntax or when the syntactic 
structure is very complex (62).  
SECTION (B) III: P300 
The P300 event related potential (ERP) has received special interest in the 
field of information processing research. The long latency P300 is described as a 
correlate for attention and basic cognitive information processing in the brain. P300 is 
a positive wave in the ERP and it occurs approximately 300 milliseconds after the 
presentation of significant, rare stimuli to the individual. There are two components in 
P300. One is the latency and other is the amplitude (63). While the amplitude 
component of P300 is representative of the amount of attention allocated for carrying 
out the task in hand, the latency of P300 indicates stimuli evaluation time by the 
individual. The traditional site for the measurement of P300 is the midline site 
particularly in the parietal region because maximal response is consistently found in 
this site. By using functional MRI, many cerebral structures have been identified as 
the potential sites for the generation of P300. Most studies have shown that the 
consistent site for the generation of P300 in the brain is the temporal lobe with few 
contributions from frontal lobe, inferior parietal lobe, amygdala, hippocampus and 
brainstem. When the attention is used actively to discriminate between two different 
stimuli, P300 is produced. This can be readily elicited by using the “oddball” 
paradigm. In this “oddball” paradigm, the individual is instructed to select low 
probability stimuli which occur randomly when a volley of high probability stimuli 
are presented.  
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Many cognitive constructs have been implicated for the variations in the 
amplitude and latency of P300 when recorded (36). These cognitive constructs 
include attention, decision making and speed of processing. The variations in P300 by 
these variables can be observed in various experimental procedures. But till date, the 
exact functional role of P300 is not clear. However, various theories by researches 
prevail to explain the generation of P300. Posner et al., proposed the “channel-limited 
information processing” in which P300 reflects the allocation of limited attentional 
resources to serve the task in hand which is relevant for the situation (64). This has 
been shown by studies where the amplitude of the P300 is attenuated when the 
individual is not attending to the target stimuli while there is a robust increase in the 
amplitude when the stimuli is given attention. Another researcher has conceptualized 
the P300 as a measure of “physiological correlate of updating of a cognitive 
hypothesis” (65). It suggests that the P300 reflects a change in the mental model of 
the environment produced by working memory. 
SECTION (B) IV: The P300 ERP in schizophrenia 
The first report of the reduction in the amplitude of P300 event related 
potential in patients with schizophrenia was given by Roth and Cannon in 1972. In 
their study, the recordings were done using the electrodes placed in midline of the 
head (66). Most of the studies that had been done after this had reported a similar 
reduction in amplitude of P300 when measured over the central plane in patients with 
schizophrenia. Some studies have reported onset delay in P300 occurrence (67). In a 
meta-analysis by Bramon et al., it was  found that an effect size of 0.85 for amplitude 
and 0.57 for latency (for both, p < 0.001) and this effect was not due to the influence 
of the antipsychotic medications taken by the subjects or the duration of the illness 
(9). O’Donnell et al. in a cross-sectional study observed that there was a greater rate 
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of decrease in latency of P300 with increasing age in patients with schizophrenia (68). 
This finding of this study is compatible with the idea of progression of the 
abnormalities in P300 in patients with schizophrenia with age but definitive evidences 
could be obtained only by longitudinal studies.  
The reduction in the amplitude of P300 in patients with schizophrenia have no 
relation with the absence of motivation in them to follow the task during the test (69). 
Ford et al. proved that in their studies, P300 remains reduced even when the patients 
were able to detect the tone as comparable to controls. The P300 latency varies with 
the difficulty of the task while the amplitude of P300 remains reduced irrespective of 
the difficulty of the task (70). Hence, it is observed that the reduction in amplitude of 
P300 is a robust finding in patients with chronic schizophrenia. 
Weisbord et al. showed that even though there were reductions in the 
amplitude of P300 over both hemispheres, there was asymmetry in P300 with smaller 
voltage over the left when compared with the temporal lobe (71). Strik et al. observed 
that this selective reduction in the amplitude of P300 in schizophrenia was relatively 
specific when compared with affective psychosis patients (72).  
P300 as a marker of cognitive functioning 
P300 can be considered as an important objective marker of cognitive 
functioning of the brain. Many research conducted assess the relationship between the 
cognitive functioning, measured by neuropsychological tests, and P300 in patients 
with schizophrenia (36). Dichter and colleagues reported that overall intelligence and 
amplitude of P300 is reduced in comparison with the normal controls. In the patient 
group, while the latency of P300 is negatively correlated with the verbal and 
performance IQ, the amplitude of P300 is positively correlated with the verbal and 
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total IQ (73). In patients with chronic schizophrenia, P300 amplitude is positively 
correlated with the short-term memory and with non-perseverative errors (74).  
P300 and psychopathological symptoms 
Research findings have reported that the abnormalities in the P300 amplitude 
and latency were correlated with the negative symptoms but not positive symptoms 
(75). Liu et al., assessed the PANSS scores in patients with schizophrenia and found 
that the patients with more negative symptom score had abnormalities in P300 in the 
form of increased latency and decreased amplitude. Predominant negative symptom 
patients had prolonged latency in N1, P2, N2 and P3 waves and reduced amplitude in 
P300 when compared to the patients with predominant positive symptoms. When 
compared to normal group, P300 amplitude is reduced in both positive and negative 
symptom group of schizophrenia but P300 latency is prolonged significantly only in 
negative symptom group (76). Some studies compared the relationship between the 
positive symptoms and P300 abnormalities. It was found that the patients with 
auditory hallucinations had increased latency of P300 and reduced amplitude of P300 
(77). When patients with aggressive behaviour compared with non aggressive 
patients, the former group had more prolonged latency and more decreased amplitude 
in P300 indicating that aggressive behaviour patients has more cognitive deficits (78).  
The effect of different types of interventions on P300 
Gonul et al., assessed the amplitude and latency changes in P300 of 
schizophrenia and depression who were on the treatment with medications. They 
found out that in the case of patients with schizophrenia, after clinical improvement 
with treatment, there were only few changes in P300 amplitude and latency but in the 
case of patients with depression, after clinical improvement with antidepressants, 
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there were shortened latency and increased amplitude in P300 (79). Molina and 
colleagues did a follow up study of the patients with schizophrenia and depression for 
two years. During the acute phase of the disorder, there were abnormalities in both the 
disorder groups. In the follow up, with the resolution of clinical symptoms in both 
groups, P300 abnormities resolved over time in the depression patients but not in the 
patients with schizophrenia. This result suggests that the P300 abnormalities noted are 
stable over time. This finding was confirmed by other studies (80). In another study, it 
was found that the no difference in the P300 amplitude and latency in patients with 
schizophrenia before and after treatment (81). Some studies which followed up the 
first-episode patients for changes in P300 found changes in P2 and P3 in 
correspondence with clinical improvement. Most studies which compared the effects 
of different medications on the P300 amplitude and latency have found out that there 
is little difference between different antipsychotics (82).  
SECTION (B) V: The P300 ERP in the first-degree relatives of patients with 
schizophrenia 
The data from the family studies investigating the heritability of P300 
amplitude, it was found that it has a substantial genetic component (0.4 – 0.6). A 
meta-analysis by Broman et al. showed that P300 amplitude and latency had a 
moderate effect size. Further studies also mostly accepted this result (9). Hall et al. 
done a twin study and showed that substantial correlation between the amplitude of 
P300 and genetic risk of schizophrenia (83). In an association study by Mulert et al. it 
was reported that P300 amplitude had positive finding with several candidate genes 
like D3 dopamine receptor and COMT (40). P300 reduction in amplitude is also 
associated with DISC1 translocation (84).   
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SECTION C: 
The cognitive deficits in schizophrenia are very important and of much 
clinical relevance. The study in the field of cognitive deficits in schizophrenia and 
their relatives has produced numerous publications. Therefore, selective articles have 
been reviewed and emphasis is given for those publications which have relevance to 
this thesis. These areas include cognitive deficits as risk factors, deficits in different 
cognitive domains, relationship between cognition and clinical symptoms and deficits 
in unaffected first-degree relatives of patients with schizophrenia. 
SECTION (C) I: Cognitive deficits in schizophrenia 
Patients suffering with schizophrenia have deficits in many cognitive domains: 
attention, working memory, verbal declarative memory and executive functions (85). 
However, no specific neurocognitive deficit profile present (86). Patients with 
schizophrenia present with wide combination of cognitive deficits, no particular 
profile can be expected in all the patients (86). Attenuated impairment in cognitive 
functions is present well before the onset of the illness. Even though attention is the 
frequent cognitive deficit seen in the prodromal phase of the illness, no one specific 
cognitive function can be used to predict the onset of the disorder. The impairments in 
the cognition do not directly correlate with the age, severity of symptoms, medication 
or duration of illness. Similarly the cognitive deficits do not progress but remain 
stable. Sometimes, executive functions may show an accelerated decline (87). It is 
still unresolved that whether some cognitive functions are specific for schizophrenia. 
In a meta-analysis, it is shown that patients with schizophrenia score well below the 
normal controls in different neuropsychological tests (88). Some patients do not show 
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differences in the cognitive functions when compared with normal controls bit it may 
be that their cognitive function have deteriorated from a high pre-morbid level (89). 
Cognitive impairment and clinical symptoms in schizophrenia 
The severity of the deficits in various domains of cognitive functions 
correlates well with the negative symptoms and to a lesser degree with the 
disorganized symptoms (90). Many studies show that there is usually no correlation 
between the positive symptoms like delusions and hallucinations with the cognitive 
functions. Improvement in the symptoms is not associated with the concurrent 
improvement of the cognitive functions in patients with schizophrenia (91). Negative 
symptom patients have poor performance in impaired conceptual thinking, object 
naming, verbal fluency and memory. The cognitive dysfunctions can be related to the 
various aspects of symptometology and these underlying cognitive deficits prevent the 
patients from attaining the optimal adaptation required for the day today activities. 
Impairments in the executive functions, like the planning and problem solving, play 
an important role in disabling the patients from psychosocial functioning. Functional 
outcome of the patients with schizophrenia is better correlated with the cognitive 
deficits than the positive or negative symptoms (92). 
Speed of processing 
Various cognitive tests are used to measure the speed of processing (93). 
Verbal fluency was measured by the number of words starting with a given letter that 
was generated in a brief time period. The cognitive processes tapped by these tests 
measured the speed of performance (94). Reaction time was used in the speed of 
processing domain. The measure of reaction time is the elapsed time between the 
presentation of a sensory stimulus and the subsequent response.  
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Speed of information processing is considered a core cognitive deficit in 
schizophrenia. Dickinson, Ramsey & Gold made a comparison of digit symbol coding 
tasks with executive functions, concluded that the largest single impairment in 
schizophrenia was on such tasks (95). The reaction time deficits in schizophrenia have 
shown a systematic association with intelligence and many cognitive processes, such 
as executive functions, working memory, and inferential processes (96). 
Rodriguez-Sanchez et al. found that cognitive deficits in schizophrenia may be 
fundamentally determined by a slow speed of information processing (97). This 
fundamental deficit may also account for the broad diversity of symptoms and 
reduced functional capacity in schizophrenia. Andreasen et al., 1998 found that 
disruption in the circuitry connecting the thalamus, frontal cortex and cerebellum 
produced difficulty in prioritizing, processing, coordinating, and responding to 
information, the very hallmarks of schizophrenia (98). It might also be rooted in white 
matter alteration, because Dwork et al. found that processing speed is heavily 
dependent on the integrity of white matter which is abnormal in schizophrenia (99).  
Ojeda et al., and Sánchez et al., found that slowing of processing speed 
performance was related to social, clinical and functional outcomes in schizophrenia 
and specific correlates between performance and clinical symptoms were also found 
to be modulated by persistence and fluctuation of the illness (100-101). The more 
persistent the illness produces more negative impact on processing speed. In a study 
by Eberhard et al., found deficits in processing speed to deteriorate linearly with the 
number of psychotic episodes (102). 
Vigilance and attention 
Attentional dysfunctions are a core feature in schizophrenia. The impairments 
include different aspects of attentional functioning such as the ability to detect 
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relevant stimuli and to focus attention on certain relevant stimuli, while ignoring 
irrelevant stimuli at the same time, as well as to maintain attention on a stimulus until 
it is processed. 
In schizophrenia, attentional deficits mainly include problems with sustained 
attention (103), selective attention (104), and cognitive control of attention (105). It is 
found that the cognitive control of attention and selective attention has strong 
relationships to working memory while sustained attention is separable from other 
cognitive factors (106). 
The most prominent test for sustained attention is the Continuous Performance 
Test (CPT) that evaluates the ability to maintain a focused readiness to detect and 
respond to selected target stimuli over a prolonged time period (107). This typically 
involves presentations of a random series of stimuli at a rapid rate over 5-15 minutes 
with instructions to respond to a predestinated stimulus. An example of a CPT is the 
computerized Rapid Visual Information Processing (RVIP) test (108-109). 
Performance results of the CPT usually include the number of correct detections, the 
number of detection errors and reaction times for correct detections.  
Nuechterlein et al., found that performance on the CPT was consistently found 
impaired in patients with schizophrenia in target detection rates and signal/noise 
discrimination independent of clinical state and across various stages of the illness 
(107).  Cornblatt et al., and Caspi et al., observed that even prior to the first psychotic 
episode and at presentation poor ability to maintain attention were typically present 
(110-111). Liu et al., found evidence for a progressively deteriorating course of 
deficits, from moderate impairment in first episode to severe impairment in chronic 
stages (112). Kurtz et al., found poor performance in first-degree relatives of 
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schizophrenics, including the children, siblings, and parents, as well as in non-clinical 
subjects with high schizotypy scores (113). Based on these findings, it has been 
suggested that the deficit in sustained attention represents a stable trait schizophrenics. 
Gur et al., observed that a deficit in sustained attention might serve as a 
possible cognitive endophenotype for schizophrenia and therefore be a useful in 
understanding the neurobiological and genetic aspects of the illness (114). Siedman et 
al., investigated the neurobiological substrate of CPT performance using functional 
neuroimaging (115). There is an abnormally low glucose metabolic rate in medial 
frontal cortex, cingulate gyrus, medial temporal lobe, and ventral caudate during CPT 
in schizophrenic patients. Snitz, Macdonald & Carter, found that poor performance of 
CPT was related to the estimated risk for the later development of schizophrenia and 
is noticeably marked in siblings and parents of schizophrenia patients (116). 
Hallmayer et al. found that poor performance was related to specific genes and 
subtypes of schizophrenia (117). 
Green et al., observed that deficits in sustained attention resulted in difficulty 
to follow social conversations and an inability to follow important instructions 
regarding treatment and simple activities such as reading or watching television 
became laboured or impossible (118). Deficits in patients with schizophrenia are 
significant predictors of outcome, including social deficits, community functioning, 
and skills acquisition (119). 
Working memory 
Barch observed that the concept of working memory was far from unitary and 
was either an immediate memory held for a brief period or a manipulation of a limited 
amount of information (120). Goldman-Rakic et al., and Barch et al., demonstrated 
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that schizophrenia patients had deficits on a variety of verbal and spatial working 
memory tasks (120-121). McGurk et al., found that verbal working memory 
impairments were common and often moderate to severe in magnitude. Spatial 
working memory deficits were also found in schizophrenia (122). Working memory 
performance deficits occurred more severe on tasks. 
Hutton et al., found that the working memory deficits in schizophrenia patients 
showed associations with clinically important features of the illness (123). The 
difficulty in encoding and then arranging information makes it difficult for 
schizophrenia patients to handle social and interpersonal situations that require 
attention to information. Kopelowicz et al., observed that working memory 
impairments caused poor functional outcome and impairments also caused less goal-
oriented behaviour, disorganized cognitions, and failure of self-monitoring (124). 
Smith, Park & Cornblatt, found that impaired performance on working 
memory tasks predicted the development of psychotic symptoms in high-risk subjects 
and marked deficits in the prodromal phase announce the transition to psychosis 
(125). Tan, Callicott & Weinberger, observed that functional abnormalities of 
prefrontal cortex have been well established in schizophrenia and proposed in 
etiological theories of this illness (126). Working memory deficits also relate strongly 
to a variety of other cognitive domains impaired in schizophrenia that are mediated by 
prefrontal cortical regions. 
Verbal learning and memory 
The abilities involved in memory functioning includes learning new 
information, retaining newly learned information over time, and recognizing 
previously presented material. Saykin et al., found that the ability to encode and retain 
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verbally presented information tended to be the most severely impaired in patients 
with schizophrenia (127). This is evidenced in reduced rates of immediate and 
delayed recall on verbal list-learning tasks such as the Buschke Selective Reminding 
Test. Smith et al., 1999 found that verbal memory performance predicted success in 
various forms of verbal therapy and was associated with social, adaptive, and 
occupational success. Bozikas et al., found that the degree of impairment in verbal 
learning and memory, unlike in other cognitive domains, is different between male 
and female schizophrenia patients, with women outperforming men, which is typical 
of the healthy population as well (128). 
Gur et al., observed that deficits in verbal learning and memory were related to 
the deficits in medial temporal and the frontal lobes (114). Both of these brain regions 
mediate component processes contributing to this cognitive dimension, and both are 
structurally and functionally impaired in schizophrenia. According to Leeson et al., 
impaired encoding and retrieval implicates abnormal involvement of prefrontal cortex 
whereas accelerated forgetting is attributable to medial temporal lobe dysfunction 
(129). 
Visual learning and memory 
This area of cognitive function is partially separate from verbal learning and 
memory and schizophrenia patients retain less visual information. The tests developed 
to be sensitive to this deficit of schizophrenia usually require recognition of faces 
either immediately or after a delay, memory for non familiar figures, and reproduction 
of line drawings.  By Rey-Osterrieth Complex Figure Test (RCFT) one is asked to 
reproduce a complicated line drawing, first by copying and then from memory. A 
study by Kim et al., on the differences in RCFT performance between schizophrenia 
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patients and healthy controls suggested that schizophrenia patients were deficient in 
visual retention and retrieval, and that a poor organizational strategy seems related to 
this visual memory deficit (130). 
On the contrary, visual learning and memory has been found by some studies 
by Gold et al., and Buchanan et al., to correlate modestly with functional outcome 
measures such as employment status, job tenure, psychosocial rehabilitation success, 
social functioning, and quality of life ratings (131-132). 
Reasoning and problem solving 
The concept of reasoning and problem solving is used to describe a loosely 
defined collection of processes involved in planning, cognitive flexibility, abstract 
thinking, and rule acquisition, initiating appropriate actions and inhibiting 
inappropriate actions, and selecting relevant sensory information (133).  
There are many neuropsychological tests which are used to test reasoning and 
problem solving. The most well known and most widely used is the Wisconsin Card 
Sorting Test (WCST). Addington et al., found that chronic patients with schizophrenia 
achieve fewer sorting categories than control subjects and display significantly more 
perseverative errors (134). Pantelis et al., observed that it was important to note that 
the difficulty of the WCST requires the contribution and coordination of numerous 
complex cognitive processes for successful completion (135).  
According to Elvevåg & Goldberg, the neural mechanisms by which schizophrenic 
psychopathology and dysfunctions in reasoning and problem solving arise have 
traditionally been associated with the frontal lobes (136). This view has been 
prominent ever since functional imaging studies correlated poor performance of 
patients with schizophrenia on the WCST to reduced activity of the dorsolateral 
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prefrontal cortex. However, more recent reviews indicate that functions are far more 
distributed across the cortex. Activated areas during WCST performance thus include 
dorsolateral prefrontal, parietal, orbitofrontal and temporal cortex (133, 137). 
The deficits in reasoning and problem solving are unique in schizophrenia. 
Bryson et al., found that they were present in most patients, regardless of the global 
level of cognitive function and independently of intelligence and are not confounded 
by education, medication, and duration of illness (138). Tan et al., observed that the 
co-occurrence of deficits  with the exacerbation of clinical symptoms and the clinical 
onset of illness may be explained by the fact that the prefrontal cortex, the centre of 
reasoning and problem solving, does not develop fully until young adulthood, where 
the first signs of illness usually occur (126). This synchronicity in clinical symptoms, 
specific cognitive dysfunction and neurodevelopment may be a critical determinant of 
schizophrenia morbidity. Reduced capacity in reasoning and problem solving might 
thus be a cognitive endophenotype in individuals at genetic high risk for 
schizophrenia. Meta-analysis by Sitskoorn et al., showed that the frontal-lobe tasks 
were the most consistent deficit in relatives of the patients (139). 
Hutton et al., found that patients with schizophrenia often have impaired 
ability to solve problems, to formulate strategies, and to evaluate their usefulness 
(123). This has numerous practical implications for everyday life and social activities 
and for performing tasks. Patients with impaired ability thus have difficulty in daily 
activities. Impairments are also associated with less engagement in therapy, 
medication compliance, and longer hospital stays. 
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SECTION (C) III: Cognitive deficits in relatives of patients with schizophrenia 
Studies in the past 25 years on the first-degree relatives of patients with 
schizophrenia have produced lot of results in the cognitive domain specifically in the 
memory and executive functions. Due to various methodological issues with these 
studies, it is not yet clear whether these results can be taken as a conclusive evidence 
that the cognitive dysfunction runs in the families (140). 
Cognitive deficits are present in schizophrenics at the time of onset of the 
illness and even predate it in patients. It is independent of the psychotic symptoms, 
related to the underlying neuronal dysfunction and also stable over the period of time 
(12, 141). Because of these merits of cognitive deficits, it has gained the attention as 
an endophenotype of the disorder. The importance of the endophenotype is that they 
could be used to discriminate the patients from controls (5, 142).  
The majority of the studies that have studied the cognitive function in the 
patients with schizophrenia have shown that the cognitive processes are affected in 
the relatives but to a lesser extend when compared to the patients (143). Studies 
dealing with the cognitive functions on the first-degree relatives of patients with 
schizophrenia suggest that the deficits in cognitive functions could be familial or 
genetic. In many of the studies, the cognitive deficits in relatives of schizophrenia 
found to be similar to that in patients but in a milder degree (144-146). Twin studies 
studying the cognitive deficits have shown that the deficits correlate well with the 
discordant monozygotic twins than discordant dizygotic twins (147-149). 
In a meta-analysis, Sitskoorn et al. analyzed 34 peer-reviewed studies that 
compared the cognitive functions between the patients with schizophrenia, their 
unaffected first-degree relatives and controls and it was reported that the first-degree 
relatives of patients with schizophrenia showed lesser cognitive efficacy when 
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compared to the normal controls (139). These cognitive deficits were seen in different 
cognitive domains like the memory and executive functions, with mean effect size 
being in the moderate range. Kang et al. analyzed similar studies and reported a small 
to moderate effect size of the cognitive deficits in the first-degree relatives of patients 
with schizophrenia (150). In a review done on the studies pertaining to the declarative 
memory in the relatives of patients with schizophrenia, Apples et al. reported that the 
relatives showed greater deficits on tests which required greater demand for the 
effective encoding and retrieval of the given material (145). Snitz et al., using the 
most robust methodologies, conducted a meta-analysis on the cognitive deficits in the 
first-degree relatives of patients in schizophrenia. In that it was reported that group 
differences in the individual tasks of cognitive function with effect size ranging from 
small to moderate. Test of span of apprehension showed a small effect size (d = 0.17) 
while CPT-AX/-IP false alarm test showed a medium effect size (d = 0.66) (116). The 
other areas of cognitive functions that showed strong deficits were the language, 
spatial ability, executive functions and attention/working memory. 
Significant differences in the tasks which require the continuous processing 
tasks has led to the proposal that they they require higher effort from the central 
executive functioning (144). Similarly, deficits in face recognition, working memory 
and declarative memory in the first-degree relatives of patients with schizophrenia 
have implicated the possible dysfunction in the front-temporal region of the brain 
(146). A verbal memory deficit in the relatives of patients with schizophrenia is stable 
over time and it has the strongest discriminative capacity (151). The relatives also 
showed deficits in other areas like the attention, vigilance and psychomotor response 
in the initial assessments but later there were some improvement in these deficits 
(152). These findings have been instrumental in further studies that needed to see the 
stability of the deficits in relatives of patients with schizophrenia.  
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AIMS AND OBJECTIVES 
AIM: 
The current study attempts to measure the event related potentials and 
neuropsychological performance in the patients with schizophrenia and their 
unaffected biological siblings and to compare them between the two groups and with 
the normal control group. 
OBJECTIVES: 
1. To measure and compare the P300 component of event related potential in 
patients with schizophrenia, their unaffected biological siblings and normal 
controls. 
2. To measure and compare the speed of processing, attention, working memory 
and executive functions performance in patients with schizophrenia, their 
unaffected biological siblings and normal controls. 
3. To identify the relationship between the P300 component of event related 
potential and neuropsychological tests in patients with schizophrenia, their 
unaffected biological siblings and normal controls. 
4. To identify the relationship between the P300 component of event related 
potential and severity of symptoms in patients with schizophrenia. 
5. To identify the relationship between the neuropsychological tests and severity 
of symptoms in patients with schizophrenia. 
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NULL HYPOTHESIS 
 
1. There is no difference in the P300 component of event related potential in 
patients with schizophrenia, their unaffected biological siblings and normal 
controls. 
2. There is no difference in the speed of processing, attention, working memory 
and executive functions performance in patients with schizophrenia, their 
unaffected biological siblings and normal controls. 
3. There is no relationship between the P300 component of event related 
potential and neuropsychological tests in patients with schizophrenia, their 
unaffected biological siblings and normal controls. 
4. There is no relationship between the P300 component of event related 
potential and severity of symptoms in patients with schizophrenia. 
5. There is no relationship between the neuropsychological tests and severity of 
symptoms in patients with schizophrenia. 
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MATERIALS AND METHOD 
Section (A): Sample selection:  
The current study was a case control study, conducted at the Institute of 
Mental Health, Rajiv Gandhi Government General Hospital, Chennai. The 
participants, 30 consecutive patients with paranoid schizophrenia and biological 
siblings of patients with schizophrenia, were taken from the outpatient and inpatient 
departments of Institute of Mental Health. 30 normal controls with no family history 
of psychiatric illness were selected from the general population.  
Inclusion criteria: 
1. Patients with paranoid schizophrenia according to ICD-10 using SCAN. 
2. Biological siblings of patients with schizophrenia without any psychiatric 
disorder. 
3. Normal controls with no family history of psychiatric illness. 
4. Subjects between 25 – 35 years of age. 
5. Minimum of eight years of formal education. 
6. Normal hearing by history and clinical examination. 
7. Giving informed consent. 
Exclusion criteria: 
1. Mental retardation. 
2. H/o any psychiatric illness (sibling and control group) using SCAN. 
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3. H/o concurrent neurological illness or systemic illness known to impair 
cognition. 
4. H/o head injury with loss of consciousness. 
5. H/o any substance dependence. 
6. H/o benzodiazepine or any other medication use known to impair cognition in 
the last 1 month period. 
Section (B): Instruments  
 
Clinical assessments 
I. Socio-demographic data sheet (Appendix 1): 
A structured proforma was designed to elicit information about the 
demographic details about the patients with schizophrenia, unaffected biological 
siblings of patients with schizophrenia and normal controls. 
II. Schedules for Clinical Assessment in Neuropsychiatry (WHO, 1999) (153): 
Schedules for Clinical Assessment in Neuropsychiatry (SCAN) are a manuals 
created by the World Health Organization (WHO) for assessing, measuring and 
classifying the mental illnesses. It can be used in variety of settings like the clinical 
and research settings. Its stability and validity has been proven by various studies.  
SCAN is a semi structured standardized clinical interview with provision for 
cross examination of the subject. There is no fixed order of the flow of the interview 
which makes this instrument flexible and versatile. Each section of the schedules 
starts with the important questions about the symptoms pertaining to that section. If 
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these questions are answered positively, then the questions below the cut-off point are 
also asked to the patient. 
III. Positive and negative syndrome scale (kay, 1987) (154): 
The patients with schizophrenia were administered the positive and negative 
syndrome scale (PANSS) to measure the severity of psychopathology. The PANSS, 
developed by SR Kay et al., is a 30-item rating scale developed to assess the 
symptoms in patients with schizophrenia and finds application in various clinical and 
research settings. This scale is based on the premises that schizophrenia has two 
distinct syndromes, positive and negative syndrome. The patient is rated from 1 to 7 
on 30 different symptoms based on the interview as well as reports of family 
members. The scale is divided into three sections, namely positive scale, negative 
scale and general psychopathology scale. PANSS is relatively a brief interview which 
takes about 40 minutes to complete.  
Neuropsychological assessments 
Test for speed of processing: 
The tests for speed of processing can be divided into two types, namely motor 
speed and mental speed. Mental speed is a composite measure which needs rapid 
information processing. In any modality, even for simple stimulus, information 
processing speed depends on the coordination of different brain circuits. The 
measurement of mental speed is used to document the efficiency of the rate of 
information processing. 
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I. Digit symbol substitution test (155): 
It is a test for visual motor coordination, motor persistence and most 
importantly response speed. The test consists of sheet in which numbers 1 – 9 are 
randomly arranged in 4 rows of 2 squares each. The subject substituted each number 
with a symbol using number symbol key given on the top of the page. The test sheet 
was placed in front of the person and asked to perform the test after explaining it. The 
subject was explained that he would be given 90 seconds and he had to as many 
symbols as possible by that time. The number correct responses were taken as the 
score of the test.  
Tests for attention: 
Attention is very basic for higher order cognition. Attention can be viewed 
either as a resource/capacity or as a skill of resource deployment. Attention is divided 
into three types namely, focused attention, sustained attention and divided attention.  
A. Sustained attention 
I. Digit vigilance test (156): 
It consists of numbers from 1 to 9 arranged randomly in rows on a page. Each 
test page contains 50 rows, each row containing 30 digits. The subject was asked to 
strike the target digits namely 6 and 9. The subjects were asked to cancel the digits as 
fast as possible without missing them or striking the wrong digits. Time taken and 
error score were calculated from the test. 
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B. Focused attention 
I. Trail making test A and B (157): 
Trail Making Test has two parts A and B. While Trail Making Test A is used 
to measure the attentional process, Trail Making Test B is used to measure the 
executive function domain. Each part consists of 25 circles distributed over a sheet of 
paper. In Part A, the circles are numbered 1 – 25, and the subject was asked to draw 
lines connecting the numbers in ascending order. In Part B, the circles include both 
numbers (1 – 13) and letters (A – L); the subject was asked to connect the circles in an 
ascending order, but the additional task is alternating between numbers and letters 
(i.e., 1-A-2-B-3-C, etc.). The subject was instructed to connect the circles as quickly 
as possible, without lifting the pen or pencil from the paper. Time taken to complete 
the trail was noted. If the subject makes an error, it was pointed out immediately and 
correction allowed. 
C. Divided attention 
I. The triads test (158): 
The triads test was developed in NIMHANS. It combines a verbal triad task 
with a tactual number identification test. For this test, the subject is blindfolded. The 
verbal triads consist of 16 triads. In each triad, two words belong to a particular 
category and the other will be the odd one. The subject had to identify the odd word 
from the triad. At the same time, a number was written with a finger in the non 
dominant hand of the subject. The subject had to identify the number also. This task 
required the divided attention to answer both the question correct at the same time. 
The number of errors committed in the each task was counted. 
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Tests for working memory: 
The main function of working memory is to hold the information at hand and 
to manipulate it according to the needs of the ongoing process. Working memory is 
externally and internally guided. 
A. Verbal working memory 
I. Verbal N – back test (Smith and Jonides, 1999)  (159): 
The N back tests used for verbal working memory, are the 1 back and 2 back 
version of the N back test. This test measures the externally guided working memory. 
In this test 30 randomly ordered consonants common to multiple Indian languages 
were presented to the subjects. One word was given to the subject per second. Of 
these 9 consonants are repeated. The constantans were repeated at random. In the case 
of 1 back test, the subject was asked to  respond when a consonant was repeated 
consecutively. Whereas in the 2 back test, the subject was instructed to respond when 
a consonant was repeated after an intervening consonant. The number of hits was 
scored along with the errors. Errors included the number of omission and commission 
errors. The total number of errors was taken for computation. 
B. Visual working memory 
I. Visual N – back test (Smith and Jonides, 1999)  (159): 
For testing visual working memory N back test with 1 back version, from the 
NIMHANS neuropsychology battery, 2004 is used. It consists of 36 cards. A black 
dot is placed randomly along the circle imagined to be on the card, in each card. The 
subject was asked to respond when they would see the location of the dots in the 
subsequent cards was repeated. The number of hits was scored along with the errors. 
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Errors included the number of omission and commission errors. The total number of 
errors was taken for computation. 
Tests for executive functions 
A. Fluency 
I. Phonemic fluency 
Controlled Oral Word Association Test (Benton & Hamsher, 1989) 
The Controlled Oral Word Association Test (COWA) is a test to measure the 
phonemic fluency. In this test the subjects generate words that are phonetically 
similar. The subject generates words that are beginning with the letters F, A, S. while 
generating words starting with these letters, the subject should exclude proper nouns 
and names of numbers. The same word should not be repeated again. In the subjects, 
whose mother tongue is not English, they are asked to generate words starting with 
“Ka”, “Pa” and “Ma”. The total number of acceptable new words produced by the 
subject in one minute for each trail is noted down and the average number of new 
words produced at the end of three trails is taken as the score.  
II. Category fluency 
Animal names test (Lezak, 1995) 
Category fluency is another form of verbal fluency. In category fluency the 
content of the words are regulated by the participant. In this type of tests, participant 
generates words that are belonging to a particular semantic category. The Animal 
names test requires the subject to generate names of the animals for one minute. The 
subject is asked to exclude the names of the fish, birds and insects. The number of 
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animal names generated by the subject in one minute forms the score of the fest. This 
test approximately takes three minutes to complete.  
B. Response inhibition 
I. Stroop test (Alexander, Benson and Stuss, 1989) (160): 
This test measures the response inhibition ability. The name of the colors 
“blue”, “green”, “red” and “yellow” are in the capital letters printed on the paper. The 
color in which the word written occasionally corresponds with the meaning of the 
color the word designated to. In this test, the words were printed in 16 rows and 11 
columns in a sheet of paper. The sheet of paper containing this was placed before the 
subject. In the first trail, the subject was asked to read the word in column wise 
ignoring the color in which the word was written. The subjects were encouraged to 
read as fast as possible. The time taken to complete the whole words was noted down 
in seconds. Once the trail was over, now the subject was asked to read the color in 
which each word was written ignoring the color represented by the word. In this trail 
also, the subjected is encouraged to read as fast as possible in column wise. The time 
taken to complete was noted down in seconds. Errors in both the trails were also 
noted. The test was given in the mother tongue of the subjects while English version 
was given to the subjects preferred it. Stroop effect score = Time taken to name – 
Time taken to read the words . 
Electrophysiological assessments 
P300 event related potential recording (161): 
RMS neuro diagnostic system was used to record P300 auditory event related 
potentials. For the purpose of this study, the oddball paradigm was developed in the 
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following manner. The auditory stimuli were presented to the subjects in both the ears 
using head phones. The auditory stimuli were pure tones presented to the subjects at 
the rate of 1.25 s for 10 min. Each tone was 100 ms in duration at an intensity of 70-
db sound level. The pure tones were of 1000 and 2000 hz in which the rare frequency 
would be the 2000hz. The probability of the occurrence of the rare frequency pure 
tone was set at 0.2. The subjects who were being tested were instructed to press a 
button using the right thumb as soon as they hear the rare target stimuli.  
Using the copper electrodes, the EEG of the subject was recorded at three sites 
namely, Fz, Cz and Pz. The electrodes were placed in the scalp of the subjects 
according to the 10-20 international system of electrode placement. The reference 
electrode was the electrode attached to the earlobes or mastoids while the ground 
electrode was placed on the left side of the forehead. 
In this, first the subjects were explained about the procedure and the doubts 
regarding it were explained. Before the start of the procedure, the subjects were asked 
to have their head washed with water and it was made sure that it was not greasy since 
it can affect the conductance.  Then the subject was comfortably seated in front of the 
computer and asked to relax. The 3 electrodes were placed on the head according to 
the 10-20 international system. Ear phones were given and asked the subject to wear 
it. Any discomfort was asked for and rectified. The subject was instructed to press a 
button or to count in his head whenever he hears the odd frequency sound and not 
respond to the repetitive, non-target sound. The recordings were stored in the 
computer and were used for further analysis.  
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Methodology of selection and administration of tests: 
Subjects were selected from the psychiatry OPD, Institute of Mental Health, 
Madras Medical College, Chennai. The subjects were selected by using the inclusion 
and exclusion criteria mentioned above. The subjects who were satisfying the criteria 
were included in the study after explaining about the study. Written informed consent 
was obtained from them before the start of the study. The neuropsychological tests 
and electrophysiological tests were done in two separate days. The 
neuropsychological tests were performed by the subjects in the Institute of Mental 
Health, Madras Medical College. The tests were given in the afternoon from 3 pm to 
5 pm. Any difficulties in the subject were asked for and were eliminated at that time. 
The electrophysiological tests were performed on the subjects in the Institute of 
Physiology, Madras Medical College. The electrophysiological and 
neurophysiological tests were conducted in distraction free silent rooms. The test 
results were recorded in the proforma as soon as the tests were finished by the 
subjects. Digital stop watch was used to measure the time taken by the subjects to 
complete the neurophysiological tests.   
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APPENDIX I 
RESULTS  
 
110 participants 
90 subjects selected 
20 participants 
excluded as they did 
not meet selection 
30 subjects with 
paranoid 
schizophrenia
30 subjects having a 
sibling with 
schizophrenia 
30 control subjects 
Socio-demographic profile 
PANSS 
P300 event related potential measurement 
Digit symbol substitution test 
Digit vigilance test 
Trail making test A and B 
Triads test 
Verbal N-back test 
Visual N-back test 
Controlled word association test 
Animal names test 
Stroop test 
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DATA ANALYSIS 
The results were tabulated and analyzed using the statistical package,  
SPSS 16.0. 
Descriptive statistics was used to get the mean and standard deviations with 
respect to different variables of socio-demographic profile of the three groups and the 
illness characteristics of the patients with schizophrenia. Age across the three groups 
was compared using ANOVA while the other socio-demographic variables were 
compared between the three groups by chi-square test. 
The event related potentials, P300 amplitude and latency were compared 
between the three groups using ANOVA. Post hoc comparisons between two different 
were also done. Similarly, neuropsychological test scores were also compared 
between the groups using ANOVA. Means score plot was used to represent the means 
of the test scores in the three groups. 
Pearson correlation was used to assess the relationship between the P300 
variables and the neuropsychological test scores. Similarly, Pearson correlation was 
used to assess the relationship between the clinical variables of the illness and event 
related potentials and neuropsychological test scores. 
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RESULTS 
The current study is case control study. Here, controls represent the subjects 
with no psychiatric illness and with no family history of psychiatric illness. Siblings 
group represent the subjects who do not have any psychiatric illness but have a patient 
with schizophrenia as their sibling. Patient group represents the subjects with paranoid 
schizophrenia. 
90 subjects were included in the current study with 30 subjects in each group. 
The subjects were selected from the outpatient department, Institute of Mental Health, 
Madras Medical College, Chennai. 
Socio-demographic data: 
Age: 
Table 1: comparison of age between the three groups 
Group  N Mean age S.D. F Sig.  
Controls  30 28.67 3.044 .008 .992 
Siblings  30 28.57 3.059 
Patients  30 28.63 3.090 
Total  90 28.62 3.030 
Significance p< 0.05 
The mean age of the group was 28.62±3.03. The mean age of the control 
group was 28.67, while it was 28.57 for siblings and 28.63 for the patient group. The 
above table shows that there was no statistical difference between the three groups 
with respect to age and hence they were comparable with respect to age. 
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Chart 1: Means graph for the age among the three groups 
 
Gender: 
Table 2: comparison of gender between the three groups 
Gender  Controls 
N 
Siblings  
N 
Patients  
N 
Total  
N 
Sig. 
Male  17 14 17 48 .669 
Female  13 16 13 42 
Total  30 30 30 30 
Significance p< 0.05 
The total number of males in the study population was 48 while the number of 
female in the study population was 42. The above table shows that the three groups 
were not statistically different with respect to gender as the chi-square valve was 
0.669 and hence comparable. 
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Chart 2: bar diagram for the distribution of sex in the three groups 
 
Education: 
Chart 3: Bar diagram for the distribution of education in  
years between the groups 
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Table 3: Comparison of education between the three groups 
Education   
(in years) 
Controls 
N 
Siblings 
N 
Patients 
N 
Total 
N 
Sig. 
8 8 9 8 25 .996 
9 8 8 10 26 
10 5 4 6 15 
11 3 3 2 8 
12 4 3 2 9 
13 2 3 2 7 
Total  30 30 30 90 
Significance p< 0.05 
The above table shows that there was no statistical difference between the 
three groups with respect to education. 
Occupation:  
Table 4: comparison of occupation between the three groups 
Occupation Controls 
N 
Siblings 
N 
Patients 
N 
Total 
N 
Sig. 
Clerical  0 1 0 1 .454 
Skilled  6 3 3 12 
Semiskilled  9 6 4 19 
Unskilled  7 10 9 26 
Unemployed 8 10 14 32 
Total  30 30 30 90 
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Chart 4: Bar diagram for the distribution of occupation between the groups 
 
When compared to the control group, more number of unemployed persons 
was there in the patient group but there was no statistical difference between the 
groups as the P value is > 0.05. 
Socio-economic status: 
Table 5: comparison of socio-economic status between the groups 
Socio-economic 
status 
Controls 
N 
Siblings 
N 
Patients 
N 
Total 
N 
Sig. 
Lower middle 3 3 3 9 .691 
Upper lower 24 23 20 67 
Lower  3 4 7 14 
Total  30 30 30 90 
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Chart 5: Bar diagram for the distribution of  
socio-economic status between the groups 
 
Marital status: 
Table 6: comparison of marital status between the groups 
Marital 
status  
Controls  
N 
Siblings  
N 
Patients  
N 
Total 
N 
Sig.  
Married 23 25 16 64 .203 
Divorced  0 0 2 2 
Separated  2 1 4 7 
Widowed  0 0 1 1 
Single  5 4 7 16 
Total  30 30 30 90 
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Chart 6: Bar diagram for the distribution of marital status between the groups 
 
Locality: 
Table 7: comparison of locality between the groups 
Locality  Controls  
N 
Siblings  
N 
Patients  
N 
Total 
N 
Sig. 
Urban  22 23 21 66 .980 
Semi urban 4 4 5 13 
Rural  4 3 4 11 
Total  30 30 30 90 
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Chart 7: Bar diagram for the distribution of locality between the groups 
 
Family type: 
Table 8: comparison of family type between the groups 
Family type Controls  
N 
Siblings 
N 
Patients 
N 
Total 
N 
Sig. 
Nuclear  25 16 20 61 .045 
Joint  5 14 10 29 
Total  30 30 30 90 
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Chart 8: Bar diagram for the distribution of family type between the groups 
 
The three group of the subjects were compared among themselves for the 
socio-demographic profile. There is no significant difference between the three 
groups with respect to age, sex and education. Hence the three groups are comparable 
for the further analysis and there is a lesser chance that the other variables would be 
affected by these confounding factors.  
Similarly, the other socio-demographic variables were also compared between 
the three groups. The three groups are comparable in the marital status, socio-
economic status and locality. There is a statistical difference between the three groups 
only in the variable of family type. 
  
 55
Illness characteristics of patients with schizophrenia: 
Table 9: Illness characteristics data of the patients with schizophrenia 
Illness characteristics N Mean S.D. 
Age of onset of illness (years) 30 21.83 2.321 
Duration of illness (months) 30 81.60 45.384 
Lag period for treatment (months) 30 30.47 20.217 
Duration of treatment (months) 30 51.13 29.251 
PANSS positive score 30 20.80 3.943 
PANSS negative score 30 24.90 8.239 
PANSS general psychopathology 
score 
30 52.53 13.549 
PANSS total score 30 98.23 20.433 
 
The mean age of the illness onset in the patient group was 21.83 years. The 
mean duration on the illness is 81.60 months. Most of the patient group was on anti-
psychotics during the study period and the mean duration of treatment was 51.13 
months. The severity of the illness was assessed by PANSS scale. The mean positive 
and negative score in the PANSS was 20.80±3.943 and 24.90±8.239. The mean total 
score of PANSS was 98.23±20.433.  
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Comparison of P300 variables across groups: 
P300 amplitude Fz (µV): 
Table 10: Comparison of P300 amplitude Fz (µV) among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 11.760 3.1883 77.587 .000 
Siblings  30 8.257 2.2334 
Patients  30 4.130 1.3293 
Total  90 8.049 3.9175 
Significance P < 0.05 
Chart 9: Means graph of P300 amplitude Fz (µV) among the three groups 
 
The above table shows that the three groups are statistically different from one 
another with respect to P300 amplitude Fz (µV). 
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P300 amplitude Cz (µV): 
Table 11: Comparison of P300 amplitude Cz (µV) among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 13.697 2.9122 58.131 .000 
Siblings  30 10.143 2.2531 
Patients  30 6.980 1.9808 
Total  90 10.273 3.6480 
Significance P < 0.05 
Chart 10: Means graph of P300 amplitude Cz (µV) among the three groups 
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There is a statistical difference between the three groups in the mean score of 
the amplitude Cz. The value in the patient group is reduced when compared with the 
other two groups. Similarly, siblings too have reduced value in relation to controls. 
P300 amplitude Pz (µV) 
Table 12: Comparison of P300 amplitude Pz (µV) among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 10.093 1.5642 33.691 .000 
Siblings  30 9.160 2.0399 
Patients  30 6.193 2.1143 
Total  90 8.482 2.5309 
Significance P < 0.05 
Chart 11: Means graph of P300 amplitude Pz (µV) among the three groups 
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The mean score for the patient group is 6.193±2.11 while for sibling group, it 
is 9.160±2.03. There is a statistical difference between the three groups with regard to 
this score. 
P300 latency Fz (ms): 
Table 13: Comparison of P300 latency Fz (ms) among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 332.57 2.512 31.281 .000 
Siblings  30 347.90 11.195 
Patients  30 372.07 19.099 
Total  90 350.84 25.281 
Significance P < 0.05 
Chart 12: Means graph of P300 latency Fz (ms) among the three groups 
 
 60
 There is a statistical difference between the three groups with regard to this 
variable. 
P300 latency Cz (ms): 
Table 14: Comparison of P300 latency Cz (ms) among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 333.40 39.893 9.014 .000 
Siblings  30 353.67 32.677 
Patients  30 368.13 19.493 
Total  90 351.73 34.577 
Significance P < 0.05 
Chart 13: Means graph of P300 latency Cz (ms) among the three groups 
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 When P300 latency Cz (ms) was compared between the three groups, there is 
a statistical difference among them with longer latency for the patient group. 
P300 latency Pz (ms): 
Table 15: Comparison of P300 latency Pz (ms) among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 334.53 15.874 58.089 .000 
Siblings  30 354.00 12.889 
Patients  30 373.67 13.231 
Total  90 354.07 21.246 
Significance P < 0.05 
Chart 14: Means graph of P300 latency Pz (ms) among the three groups 
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There is a statistical difference between the three groups. The sibling group is 
intermediate in latency when compared with the patient and control group. 
Comparison of neuropsychological variables across groups: 
Digit symbol substitution test, total time (seconds): 
Table 16: Comparison of Digit symbol substitution test total time (seconds) 
among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 287.50 59.167 12.368 .000 
Siblings  30 303.47 47.394 
Patients  30 345.80 29.287 
Total  90 312.26 52.574 
Significance P < 0.05 
Chart 15: Means graph of Digit symbol substitution  
test total time (seconds) among the three groups 
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There is a statistical difference between the three groups with respect to digit 
symbol substitution test. 
Digit vigilance test, total time (seconds): 
Table 17: Comparison of Digit vigilance test, total time  
(seconds) among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 554.50 81.533 17.179 .000 
 
 
 
Siblings  30 627.93 93.653 
Patients  30 675.30 63.163 
Total  90 619.24 93.924 
Significance P < 0.05 
Chart 16: Means graph of Digit vigilance test,  
total time (seconds) among the three groups 
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When three groups were compared with the above said test, there is a 
statistical difference among the three groups. 
Digit vigilance test, total errors: 
Table 18: Comparison of Digit vigilance test, total errors among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 10.87 2.886 54.171 .000 
Siblings  30 14.77 2.315 
Patients  30 18.57 3.308 
Total  90 14.73 4.245 
Significance P < 0.05 
Chart 17: Means graph of Digit vigilance test,  
total errors among the three groups 
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 In the three groups, the total errors made by the patient group is more when 
compared with the other two groups while siblings were having more errors than the 
controls. There is a statistical difference between the three groups present. 
Trail-making test, part A (seconds): 
Table 19: Comparison of Trail-making test,  
part A (seconds) among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 42.30 12.301 20.572 .000 
Siblings  30 46.63 6.105 
Patients  30 56.83 7.414 
Total  90 48.59 10.812 
Significance P < 0.05 
Chart 18: Means graph of Trail-making test,  
part A (seconds) among the three groups 
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 Trail making test, part A shows a statistical difference among the three groups 
of subjects with more time taken by the patients to complete the test when compared 
with others. The time taken by the siblings is intermediate between the other groups 
Trail-making test, part B (seconds): 
Table 20: Comparison of Trail-making test,  
part B (seconds) among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 87.23 20.903 67.251 .000 
Siblings  30 100.73 11.429 
Patients  30 133.07 13.222 
Total  90 107.01 24.817 
Significance P < 0.05 
Chart 19: Means graph of Trail-making test,  
part B (seconds) among the three groups 
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 There is a statistical difference among the three groups with respect to the 
Trail making test, part B. 
Trail-making test, part B – part A (seconds): 
Table 21: Comparison of Trail-making test,  
part B – part A (seconds) among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 45.07 11.507 92.771 .000 
Siblings  30 54.77 7.934 
Patients  30 76.23 7.171 
Total  90 58..69 15.871 
Significance P < 0.05 
Chart 20: Means graph of Trail-making test,  
part B – part A (seconds) among the three groups 
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 The difference between the Trail making test B and Trail making test A can be 
taken as an indicator of the executive function of the subjects. There is a statistical 
difference among the three groups when scores were compared. 
Triads test, total errors: 
Table 22: Comparison of Triads test, total errors among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 3.77 1.591 61.562 .000 
Siblings  30 6.67 2.040 
Patients  30 9.03 1.866 
Total  90 6..49 2.829 
Significance P < 0.05 
Chart 21: Means graph of Triads test, total errors among the three groups 
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When the three groups were compared to the scores of the Triads test, there is 
a statistical difference between the three groups is observed. The total errors made by 
the patients and siblings are more when compared with normal group. 
Verbal N-back test, 1 back hits: 
Table 23: Comparison of Verbal N-back test, 1 back hits among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 8.70 .535 3.370 .000 
Siblings  30 8.63 .615 
Patients  30 8.30 .750 
Total  90 8.54 .656 
Significance P < 0.05 
Chart 22: Means graph of Verbal N-back test,  
1 back hits among the three groups 
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Even though the scores among the three groups were comparable, there is a 
statistical difference between the three groups with regard to this test. The sibling and 
normal group were more comparable than the patient group with regard to this test. 
Verbal n-back test, 1back errors: 
Table 24: Comparison of Verbal n-back test,  
1back errors among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 .30 .535 3.370 .000 
Siblings  30 .37 .615 
Patients  30 .70 .750 
Total  90 .46 .656 
Significance P < 0.05 
Chart 23: Means graph of Verbal n-back test,  
1back errors among the three groups 
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There is a statistical difference between the three groups when they were 
compared with the mean scores of the verbal 1 back error test. 
Verbal N-back test, 2 back hits: 
Table 25: Comparison of Verbal N-back test, 2 back hits among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 7.90 .481 66.348 .000 
Siblings  30 7.50 .731 
Patients  30 5.60 1.133 
Total  90 7.00 1.298 
Significance P < 0.05 
Chart 24: Means graph of Verbal n-back test,  
2 back errors among the three groups 
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The mean scores of the verbal 2 back hits in the patient group were lower 
when compared to the other groups of the siblings and the normal group. There is a 
statistical difference between the three groups with respect to this test 
Verbal N-back test, 2 back errors: 
Table 26: Comparison of Verbal N-back test,  
2 back errors among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 1.10 .481 66.348 .000 
Siblings  30 1.50 .731 
Patients  30 3.40 1.133 
Total  90 2.00 1.298 
Significance P < 0.05 
Chart 25: Means graph of Verbal N-back test,  
2 back errors among the three groups 
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There is a statistical difference between the three groups of the patients, 
siblings and the normal group. 
Visual N-back test, 1 back hits: 
Table 27: Comparison of Visual N-back test,  
1 back hits among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 7.67 .844 67.466 .000 
Siblings  30 6.00 .910 
Patients  30 5.13 .819 
Total  90 6.27 1.356 
Significance P < 0.05 
Chart 26: Means graph of Visual N-back test,  
1 back hits among the three groups 
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The mean score of the patient group in the visual 1 back hits was lower when 
compared to the other groups. The sibling group was lower when compared with the 
normal group. There is a statistical difference between the three groups. 
Visual N-back test, 1 back error: 
Table 28: Comparison of Visual N-back test,  
1 back error among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 1.33 .844 67.466 .000 
Siblings  30 3.00 .910 
Patients  30 3.87 .819 
Total  90 2.73 1.356 
Significance P < 0.05 
Chart 27: Means graph of Visual N-back test,  
1 back errors among the three groups 
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There is a significant difference between the three groups when their mean 
scores in the above said test was compared. Patient group performed worst in the 
three groups while the sibling group was worse when compared with the normal 
group. 
Visual N-back test, 2 back hits: 
Table 29: Comparison of Visual N-back test, 2 back hits among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 5.40 .894 51.887 .000 
Siblings  30 4.13 1.074 
Patients  30 2.93 .828 
Total  90 4.16 1.373 
Significance P < 0.05 
Chart 28: Means graph of Visual N-back test,  
2 back hits among the three groups 
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When the mean score in the visual 2 back hits were compared between the 
three groups, there is a statistical difference between the three groups. 
Visual N-back test, 2 back errors: 
Table 30: Comparison of Visual N-back test,  
2 back errors among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 3.60 .894 51.887 .000 
Siblings  30 4.87 1.074 
Patients  30 6.07 .828 
Total  90 4.84 1.373 
Significance P < 0.05 
Chart 29: Means graph of Visual N-back test,  
2 back errors among the three groups 
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There is a statistical difference between the three groups when they were 
compared by the scores of the visual 2 back error test. 
Controlled oral word association test, average new words: 
Table 31: Comparison of Controlled oral word association test,  
average new words among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 8.70 2.136 20.086 .000 
Siblings  30 7.40 1.831 
Patients  30 5.73 1.413 
Total  90 7.28 2.172 
Significance P < 0.05 
Chart 30: Means graph of Controlled oral word association test,  
average new words among the three groups 
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There is statistical difference between the three groups compared with respect 
to this test. Patients and siblings scored lower when compared with the normal 
controls. 
Animal names test, total new words: 
Table 32: Comparison of Animal names test,  
total new words among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 13.03 1.691 42.001 .000 
Siblings  30 11.07 1.639 
Patients  30 9.13 1.613 
Total  90 11.08 2.284 
Significance P < 0.05 
Chart 31: Means graph of Animal names test,  
total new words among the three groups 
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The patient group performed worse when compared with the sibling and 
normal group and the sibling group performed well when compared with the patient 
group while worse when compared with the normal group. There is a statistical 
difference between the three groups  
Stroop test, stroop effect (seconds): 
Table 33: Comparison of Stroop test,  
stroop effect (seconds) among the three groups 
Group  N Mean  S.D. F Sig. 
Controls  30 152.43 2.146 124.756 .000 
Siblings  30 200.80 30.897 
Patients  30 261.10 23.479 
Total  90 204.78 51.913 
Significance P < 0.05 
Chart 32: Means graph of Stroop test,  
stroop effect (seconds) among the three groups 
 
There is a statistical difference between the three groups when they were 
compared using the stroop test. 
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Table 34: Correlation between the illness characteristics and P300 amplitude 
 
From the correlation analysis, it is found that the P300 amplitude are having a 
strong correlation with the age of onset of the illness, duration of illness and the 
duration of treatment. There is a negative correlation between the P300 amplitude and 
the PANSS negative score and the PANSS general psychopathology score. Also, 
there is a negative correlation between the PANSS total score and the P300 amplitude 
Illness 
characteristics 
Correlations P300 
amplitude 
Fz 
P300 
amplitude 
Cz 
P300 
amplitude 
Pz 
Age of onset of 
illness (years) 
Pearson 
correlation .595
** .506 .610** 
Sig. .001 .004 .000 
Duration of 
illness (months) 
Pearson 
correlation -.403
** -.409** -.506 
Sig. .027 .025 .004 
Lag period for 
treatment 
(months) 
Pearson 
correlation -.363 -.340
** -.374** 
Sig. .049 .066 .042 
Duration of 
treatment 
(months) 
Pearson 
correlation -.374
** -.400* -.527** 
Sig. .042 .029 .003 
PANSS positive 
score 
Pearson 
correlation -.020 -.047 -.051 
Sig. .917 .804 .789 
PANSS negative 
score 
Pearson 
correlation -.175
** -.248 -.232** 
Sig. .354 .186 .216 
PANSS general 
psychopathology 
score 
Pearson 
correlation -.420
** -.384** -.377** 
Sig. .021 .036 .040 
PANSS total 
score 
Pearson 
correlation -.353
** -.364** -.353** 
Sig. .056 .048 .055 
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values. There is no correlation between the PANSS positive score and the P300 
amplitude values. 
Table 35: Correlation between the illness characteristics and P300 latency 
 
Illness 
characteristics 
Correlations P300 
latency 
Fz 
P300 
latency 
Cz 
P300 latency
Pz 
Age of onset of 
illness (years) 
Pearson 
correlation -.484
** -.413 -.645** 
Sig. .007 .023 .000 
Duration of 
illness (months) 
Pearson 
correlation .297
** .301** .278 
Sig. .111 .106 .136 
Lag period for 
treatment 
(months) 
Pearson 
correlation .220 .248
** .264** 
Sig. .242 .186 .159 
Duration of 
treatment 
(months) 
Pearson 
correlation .308
** .295* .250** 
Sig. .098 .114 .183 
PANSS positive 
score 
Pearson 
correlation .099 .049 -.090 
Sig. .604 .798 .637 
PANSS negative 
score 
Pearson 
correlation .122
** .236 .073** 
Sig. .520 .210 .702 
PANSS general 
psychopathology 
score 
Pearson 
correlation .363
** .245** .341** 
Sig. .048 .191 .065 
PANSS total 
score 
Pearson 
correlation .309
** .267** .238** 
Sig. .096 .153 .205 
 
There is significant correlation between the age of onset of illness and the 
P300 latency values. Also, there is a significant correlation between the PANSS 
general psychopathology score and the P300 latency scores. There is no significant 
correlation between the other illness characteristics and the P300. In the case of 
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relationship between the P300 and the age of onset of illness, it has a negative 
correlation.  
Table 36: Correlation between the illness characteristics, Digit symbol 
substitution test and Digit vigilance test 
 
Illness 
characteristics Correlations 
Digit symbol 
substitution 
test, total time 
(seconds) 
Digit 
vigilance 
test, total 
time 
(seconds) 
Digit 
vigilance 
test, total 
errors 
Age of onset of 
illness (years) 
Pearson 
correlation -.618 -.630
** -.587** 
Sig. .000 .000 .001 
Duration of 
illness (months) 
Pearson 
correlation .386
** .307 .466** 
Sig. .035 .099 .009 
Lag period for 
treatment 
(months) 
Pearson 
correlation .353
** .261** .422 
Sig. .056 .164 .020 
Duration of 
treatment 
(months) 
Pearson 
correlation .354
* .296** .431** 
Sig. .055 .112 .017 
PANSS positive 
score 
Pearson 
correlation .032 .075 .002 
Sig. .867 .693 .990 
PANSS negative 
score 
Pearson 
correlation .139 .141
** .214** 
Sig. .465 .456 .256 
PANSS general 
psychopathology 
score 
Pearson 
correlation .362
** .345** .415** 
Sig. .050 .062 .023 
PANSS total 
score 
Pearson 
correlation .302
** .300** .362** 
Sig. .105 .107 .050 
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Digit vigilance test has a strong correlation with the age of onset of illness. 
These two variables have a negative correlation between them. Similarly, PANSS 
general psychopathology score has a significant correlation with the digit vigilance 
test. These is no significant correlation between the other test and the illness 
characteristics. 
Table 37: Correlation between the illness characteristics and  
Trail making test, part A and part B 
 
Illness 
characteristics Correlations 
Trail-
making 
test, part A 
(seconds) 
Trail-making 
test, part B 
(seconds) 
Trail-making 
test, part B - 
part A 
(seconds) 
Age of onset of 
illness (years) 
Pearson 
correlation -.587
** -.599 -.497** 
Sig. .001 .000 .005 
Duration of 
illness (months) 
Pearson 
correlation .466
** .545** .523 
Sig. .009 .002 .003 
Lag period for 
treatment 
(months) 
Pearson 
correlation .422 .438
** .371** 
Sig. .020 .016 .044 
Duration of 
treatment 
(months) 
Pearson 
correlation .431
** .543* .555** 
Sig. .017 .002 .001 
PANSS positive 
score 
Pearson 
correlation .002 .105 .192 
Sig. .990 .579 .310 
PANSS negative 
score 
Pearson 
correlation .214
** .355 .433** 
Sig. .256 .054 .017 
PANSS general 
psychopathology 
score 
Pearson 
correlation .415
** .477** .450** 
Sig. .023 .008 .013 
PANSS total 
score 
Pearson 
correlation .362
** .480** .510** 
Sig. .050 .007 .004 
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Trail making test, both part A and part B has a significant correlation with all 
the illness characteristics except the PANSS positive and negative score. Trail making 
test show a significant correlation with the age of onset of illness and duration of 
illness.  
Table 38: Correlation between the illness characteristics,  
Triads test and Verbal 1-back test 
 
Illness 
characteristics Correlations 
TRIADS 
TEST, 
TOTAL 
ERRORS 
VERBAL 
N-BACK 
TEST, 1 
BACK 
HITS 
VERBAL N-
BACK TEST, 
1 BACK 
ERRORS 
Age of onset of 
illness (years) 
Pearson 
correlation -.604
** .525 -.525** 
Sig. .000 .003 .003 
Duration of 
illness (months) 
Pearson 
correlation .553
** -.428** .428 
Sig. .002 .018 .018 
Lag period for 
treatment 
(months) 
Pearson 
correlation .473 -.483
** .483** 
Sig. .008 .007 .007 
Duration of 
treatment 
(months) 
Pearson 
correlation .531
** -.331* .331** 
Sig. .003 .074 .074 
PANSS positive 
score 
Pearson 
correlation -.032 -.049 .049 
Sig. .867 .797 .797 
PANSS negative 
score 
Pearson 
correlation .245
** -.196 .196** 
Sig. .192 .299 .299 
PANSS general 
psychopathology 
score 
Pearson 
correlation .485
** -.393** .393** 
Sig. .007 .032 .032 
PANSS total 
score 
Pearson 
correlation .414
** -.349** .349** 
Sig. .023 .059 .059 
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Verbal and visual N-back tests have a significant correlation with all the 
illness characteristics of the patient group except the PANSS positive and negative 
scores.  
Table 39: Correlation between the illness characteristics,  
Verbal 2-back test and Visual 1-back test 
Illness 
characteristics Correlations 
VERBAL N-
BACK TEST, 
2 BACK 
HITS 
VERBAL N-
BACK TEST, 
2 BACK 
ERRORS 
VISUAL N-
BACK 
TEST, 
1BACK 
HITS 
Age of onset of 
illness (years) 
Pearson 
correlation .472
** -.472** .538** 
Sig. .008 .008 .002 
Duration of 
illness (months) 
Pearson 
correlation -.349
** .349** -.447 
Sig. .058 .058 .013 
Lag period for 
treatment 
(months) 
Pearson 
correlation -.220 .220 -.408
** 
Sig. .242 .242 .025 
Duration of 
treatment 
(months) 
Pearson 
correlation -.390
** .390** -.412** 
Sig. .033 .033 .024 
PANSS positive 
score 
Pearson 
correlation -.049 .049 -.002 
Sig. .795 .795 .991 
PANSS negative 
score 
Pearson 
correlation -.256
** .256** -.274** 
Sig. .173 .173 .143 
PANSS general 
psychopathology 
score 
Pearson 
correlation -.363
** .363** -.426** 
Sig. .049 .049 .019 
PANSS total 
score 
Pearson 
correlation -.353
** .353** -.393** 
Sig. .055 .055 .032 
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Verbal and visual N-back tests have a significant correlation with all the 
illness characteristics of the patient group except the PANSS positive and negative 
scores.  
Table 40: Correlation between the illness characteristics and visual N-back tests 
Illness 
characteristics Correlations 
VISUAL N-
BACK 
TEST, 1 
BACK 
ERRORS 
VISUAL N-
BACK 
TEST, 2 
BACK HITS 
VISUAL N-
BACK TEST, 
2 BACK 
ERRORS 
Age of onset of 
illness (years) 
Pearson 
correlation -.538
** .335 -.335** 
Sig. .002 .070 .070 
Duration of 
illness (months) 
Pearson 
correlation .447
** -.390** .390 
Sig. .013 .033 .033 
Lag period for 
treatment 
(months) 
Pearson 
correlation .408 -.324
** .324** 
Sig. .025 .081 .081 
Duration of 
treatment 
(months) 
Pearson 
correlation .412
** -.381* .381** 
Sig. .024 .038 .038 
PANSS positive 
score 
Pearson 
correlation .002 -.046 .046 
Sig. .991 .807 .807 
PANSS negative 
score 
Pearson 
correlation .274
** -.203 .203** 
Sig. .143 .281 .281 
PANSS general 
psychopathology 
score 
Pearson 
correlation .426
** -.301** .301** 
Sig. .019 .106 .106 
PANSS total 
score 
Pearson 
correlation .393
** -.291** .291** 
Sig. .032 .119 .119 
 
Verbal and visual N-back tests have a significant correlation with all the 
illness characteristics of the patient group except the PANSS positive and negative 
scores.  
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Table 41: Correlation between the illness characteristics, Controlled oral word 
association test, Animal names test and Stroop test 
 
Illness 
characteristics Correlations 
CONTOLLED 
ORAL WORD 
ASOCIATION 
TEST, 
AVERAGE 
NEW WORDS 
ANIMAL 
NAMES 
TEST, 
TOTAL 
NEW 
WORDS 
STROOP 
TEST, 
STROOP 
EFFECT 
(SECONDS) 
Age of onset of 
illness (years) 
Pearson 
correlation .596
** .402 -.625** 
Sig. .001 .028 .000 
Duration of 
illness (months) 
Pearson 
correlation -.327
** -.250** .428 
Sig. .078 .183 .018 
Lag period for 
treatment 
(months) 
Pearson 
correlation -.302 -.180
** .443** 
Sig. .105 .342 .014 
Duration of 
treatment 
(months) 
Pearson 
correlation -.298
** -.263* .358** 
Sig. .110 .160 .052 
PANSS positive 
score 
Pearson 
correlation .052 -.196 -.091 
Sig. .785 .299 .631 
PANSS negative 
score 
Pearson 
correlation -.228
** .024 .205** 
Sig. .227 .898 .277 
PANSS general 
psychopathology 
score 
Pearson 
correlation -.363
** -.182** .433** 
Sig. .048 .337 .017 
PANSS total 
score 
Pearson 
correlation -.323
** -.148** .352** 
Sig. .082 .434 .056 
 
Stroop test has a significant correlation with the age of onset of illness, 
duration of treatment and lag period of treatment. It also shows a strong correlation 
with the PANSS general psychopathology score and the total score. 
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Table 42: Correlation between neuropsychological tests and P300 amplitude 
 
Neuropsychological 
tests Correlations 
P300 
amplitude 
Fz 
P300 
amplitude 
Cz 
P300 
amplitude 
Pz 
Digit symbol 
substitution test, 
total time (seconds) 
Pearson 
correlation -.784 -.794
* -.803* 
Sig. .000 .000 .000 
Digit vigilance test, 
total time (seconds) 
Pearson 
correlation -.888 -.811
** -.860* 
Sig. .000 .000 .000 
Digit vigilance test, 
total errors 
Pearson 
correlation -.758 -.723
** -.803 
Sig. .000 .000 .000 
Trail-making test, 
part A (seconds)) 
Pearson 
correlation -.798 -.712 -.860 
Sig. .000 .000 .000 
Trail-making test, 
part B (seconds) 
Pearson 
correlation -.790 -.766 -.872 
Sig. .000 .000 .000 
Trail-making test, 
part B - part A 
(seconds) 
Pearson 
correlation -.632 -.676 -.718 
Sig. .000 .000 .000 
TRIADS TEST, 
TOTAL ERRORS 
Pearson 
correlation -.832 -.862 -.833 
Sig. .000 .000 .000 
 
Verbal and visual N-back tests have a significant correlation with all the 
illness characteristics of the patient group except the PANSS positive and negative 
scores. There is significant correlation between the digit vigilance test and the central 
and parietal electrode measurements. There is no significant correlation between the 
P300 amplitude Fz and the neuropsychological tests.  
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Table 43: Correlation between neuropsychological tests and P300 amplitude 
 
Neuropsychological 
tests Correlations 
P300 
amplitude 
Fz 
P300 
amplitude 
Cz 
P300 
amplitude 
Pz 
VERBAL N-BACK 
TEST, 1 BACK 
HITS 
Pearson 
correlation .783 .738 .593 
Sig. .000 .000 .001 
VERBAL N-BACK 
TEST, 1 BACK 
ERRORS 
Pearson 
correlation -.783 -.738 -.593 
Sig. .000 .000 .001 
VERBAL N-BACK 
TEST, 2 BACK 
HITS 
Pearson 
correlation .753 .780 .694 
Sig. .000 .000 .000 
VERBAL N-BACK 
TEST, 2 BACK 
ERRORS 
Pearson 
correlation -.753 -.780 -.694 
Sig. .000 .000 .000 
VISUAL N-BACK 
TEST, 1BACK 
HITS 
Pearson 
correlation .731 .605 .769 
Sig. .000 .000 .000 
VISUAL N-BACK 
TEST, 1 BACK 
ERRORS 
Pearson 
correlation -.731 -.605 -.769 
Sig. .000 .000 .000 
VISUAL N-BACK 
TEST, 2 BACK 
HITS 
Pearson 
correlation .695 .674 .717 
Sig. .000** .000 .000** 
VISUAL N-BACK 
TEST, 2 BACK 
ERRORS 
Pearson 
correlation -.695 -.674 -.717 
Sig. .000** .000** .000 
 
Verbal and visual N-back tests have a significant correlation with all the 
illness characteristics of the patient group except the PANSS positive and negative 
scores. Visual 2-back test shows a significant correlation with the P300 amplitude. 
Visual 2-back hits have a positive correlation with the P300 amplitude while the 
visual 2-back errors have a negative correlation with the P300 amplitude. 
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Table 44: Correlation between neuropsychological tests and P300 amplitude 
 
Neuropsychological 
tests 
Correlations P300 
amplitude
Fz 
P300 
amplitude 
Cz 
P300 
amplitude 
Pz 
CONTOLLED 
ORAL WORD 
ASOCIATION 
TEST, AVERAGE 
NEW WORDS 
Pearson 
correlation .772 .787 .675 
Sig. .000 .000** .000** 
ANIMAL NAMES 
TEST, TOTAL 
NEW WORDS 
Pearson 
correlation .657 .546 .626 
Sig. .000** .002* .000** 
STROOP TEST, 
STROOP EFFECT 
(SECONDS) 
Pearson 
correlation -.783 -.722 -.768 
Sig. .000 .000 .000 
 
There is a significant correlation between the Animal names test and 
Controlled oral association test with the P300 amplitude scores. There is no 
significant correlation between the Stroop test and the P300 amplitude scores. 
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Table 45: Correlation between neuropsychological tests and P300 latency 
 
Neuropsychological 
tests Correlations 
P300 
latency 
Fz 
P300 latency 
Cz 
P300 
latency 
Pz 
Digit symbol 
substitution test, 
total time (seconds) 
Pearson 
correlation .844 .796
* .740* 
Sig. .000 .000 .000 
Digit vigilance test, 
total time (seconds) 
Pearson 
correlation .903 .864
** .911* 
Sig. .000 .000 .000 
Digit vigilance test, 
total errors 
Pearson 
correlation .846 .714
** .884 
Sig. .000 .000 .000 
Trail-making test, 
part A (seconds)) 
Pearson 
correlation .889 .807 .836 
Sig. .000 .000 .000 
Trail-making test, 
part B (seconds) 
Pearson 
correlation .898 .835 .813 
Sig. .000 .000 .000 
Trail-making test, 
part B - part A 
(seconds) 
Pearson 
correlation .736 .706 .635 
Sig. .000 .000 .000 
TRIADS TEST, 
TOTAL ERRORS 
Pearson 
correlation .841 .779 .843 
Sig. .000 .000 .000 
 
There is a significant correlation between the digit vigilance test and the P300 
latency. Particularly, there is a significant correlation between the P300 latency in the 
Cz and Pz electrode while there is no significant correlation with the Pz electrode. 
There is no correlation with the other neuropsychological tests and the P300 latency. 
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Table 46: Correlation between neuropsychological tests and P300 latency 
 
Neuropsychological 
tests Correlations 
P300 
latency 
Fz 
P300 
latency 
Cz 
P300 
latency 
Pz 
VERBAL N-BACK 
TEST, 1 BACK 
HITS 
Pearson 
correlation -.654 -.652 -.640 
Sig. .000 .000 .000 
VERBAL N-BACK 
TEST, 1 BACK 
ERRORS 
Pearson 
correlation .654 .652 .640 
Sig. .000 .000 .000 
VERBAL N-BACK 
TEST, 2 BACK 
HITS 
Pearson 
correlation -.845 -.718 -.766 
Sig. .000 .000 .000 
VERBAL N-BACK 
TEST, 2 BACK 
ERRORS 
Pearson 
correlation .845 .718 .766 
Sig. .000 .000 .000 
VISUAL N-BACK 
TEST, 1BACK 
HITS 
Pearson 
correlation -.732 -.837 -.836 
Sig. .000 .000 .000 
VISUAL N-BACK 
TEST, 1 BACK 
ERRORS 
Pearson 
correlation .732 .837 .836 
Sig. .000 .000 .000 
VISUAL N-BACK 
TEST, 2 BACK 
HITS 
Pearson 
correlation -.737 -.724 -.692 
Sig. .000** .000 .000** 
VISUAL N-BACK 
TEST, 2 BACK 
ERRORS 
Pearson 
correlation .737 .724 .692 
Sig. .000** .000** .000 
 
There is a significant correlation between the visual 2-back test and the P300 
latency. The other neuropsychological tests are not having a significant correlation 
with the P300 latency. 
 
 
 
 93
Table 47: Correlation between neuropsychological tests and P300 latency 
 
Neuropsychological 
tests Correlations 
P300 
latency 
Fz 
P300 
latency 
Cz 
P300 
latency 
Pz 
CONTOLLED 
ORAL WORD 
ASOCIATION 
TEST, AVERAGE 
NEW WORDS 
Pearson 
correlation -.844 -.724 -.843 
Sig. .000 .000** .000** 
ANIMAL NAMES 
TEST, TOTAL 
NEW WORDS 
Pearson 
correlation -.620 -.595 -.723 
Sig. .000** .001* .000** 
STROOP TEST, 
STROOP EFFECT 
(SECONDS) 
Pearson 
correlation .832 .731 .858 
Sig. .000 .000 .000 
 
There is a significant correlation between the Animal names test and 
Controlled oral word association test and the P300 latency values. There is no 
significant correlation between the Stroop test and the P300 latency. 
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DISCUSSION 
The aim of the study was to measure the event related potential, P300 and 
neuropsychological tests in patients with schizophrenia and their unaffected biological 
siblings and to compare the results with controls. The study was done after matching 
for age, sex and education among the three groups, namely the patients with 
schizophrenia, their unaffected biological siblings and controls.  
The sample, patients with schizophrenia and their siblings, was taken from the 
psychiatry outpatient department, Institute of Mental Health. This sample consisted of 
30 patients and 30 siblings. The patients with paranoid schizophrenia were selected 
according to ICD-10. The control group consisted of 30 subjects who were not having 
any family history of psychiatric illness. This sample was selected from the caregivers 
of patients in other departments excepting psychiatry. The confounding bias due to 
the age, sex and education in the measurement of electrophysiological and 
neuropsychological tests were reduced by matching the three groups for age, sex and 
education. The subjects, who were taking medications which can have an impact on 
the cognition, were excluded from the study. The mean age of the study population 
was 28.62±3.03. 
Comparison of P300 among the three groups: 
With respect toP300 amplitude measurements in the three groups of subjects, 
there was a significant difference between the three groups. The difference was more 
in the case of the amplitude measured in the central and parietal regions when 
compared with the frontal regions. The mean amplitude in the controls was 
11.760±3.18, siblings 8.257±2.23 and patients 4.130±1.32. It showed a statistical 
significance between the groups (F = 77.587). Similar results were obtained in other 
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studies which investigated the comparison between the P300 amplitude between the 
patients with schizophrenia and their unaffected siblings. The current study showed a 
difference in the amplitude as well in the latency of P300 between the groups. The 
amplitude and latency were measured in three regions of the scalp namely the frontal, 
central and parietal areas. There was a significant difference between the groups in the 
individual parameters also. Kidogami et al. showed the amplitude of P300 in the 
patients with schizophrenia and the first degree relatives of patients with 
schizophrenia was of low amplitude when compared with the control group (162). But 
there was no significant difference between the first degree relatives and patients with 
schizophrenia with respect to P300 amplitude. This showed that the P300 could be 
taken as a trait marker for schizophrenia. In another study by Black et al. observed 
that 40% of patients with schizophrenia showed P300 abnormalities while only 10% 
of first degree relatives of patients with schizophrenia showed P300 abnormalities 
(11). Similar to these studies, the current study also showed that the P300 amplitude 
was smaller in patients with schizophrenia when compared to the controls and the 
siblings of patients with schizophrenia. In the case of the siblings, the P300 amplitude 
was reduced when compared to the control group. 
The P300 latency showed significant difference between the groups. The 
latency was longer for the patients with schizophrenia while it was intermediate 
between the patients and controls in the case of the siblings. Araki et al in their study 
showed similar results that the latency was prolonged in the case of patients with 
schizophrenia when compared the controls (163). In the case of first degree relatives 
of patients with schizophrenia, the latency was prolonged when compared to the 
normal controls but they were comparable to the patient group. But a meta-analysis on 
the P300 abnormalities in the schizophrenia had showed that the changes in the 
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latency were an inconsistent finding while the changes in the amplitude showed 
robust results. 
Digit symbol substitution test: 
In this study, digit symbol substitution test was given to the subjects to assess 
the mental speed. It showed a significant difference between the groups regarding the 
mental speed. Siblings showed a slower rate of mental speed when compared with the 
control group while patients with schizophrenia had the worst performance in the test. 
In a study by Amaresha et al. it was showed that the patients with schizophrenia had a 
worse speed of processing when compared to the controls. Also, the speed of 
processing was dependent upon various clinical correlates like the negative score in 
PANSS (164). Similarly, Laurent et al showed that there was a decrease in the 
performance in the tests measuring speed of processing in the first degree relatives of 
patients with schizophrenia (165).  
Continuous performance test: 
Continuous performance test, which was applied to measure the sustained 
attention, showed a statistical difference between the three group of subjects. The 
patients with schizophrenia and their siblings performed poorly with errors when 
compared to the control group. Avila et al studied the continuous performance test in 
the schizophrenia spectrum disorders and reported that the patients with schizophrenia 
had severe impairments in the performance (166). This study showed a gradation in 
the performance with highest deficits in the patients with schizophrenia while lesser 
impairments in the patients with schizotypal personality disorder. In another study by 
Bove et al, which studied the continuous performance test in 24 first degree relatives 
of patients with schizophrenia, showed slight decrease in performance in the test 
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when compared with the control group. In this study, it was showed that the 
performance of the test in the first degree relatives was not dependent on the basic 
symptoms (167). 
Trail-making test: 
In this study, trail-making test showed that there was only slight difference 
between the groups when trail-making A test was compared between the groups. But 
these was a statistical difference between the groups was observed when trail-making 
B test was compared between the groups. This difference showed that the attention 
and set shifting deficits were the underlying problems in the case of patients with 
schizophrenia. The deficits were also evident in the siblings but not to the level of 
patients. This shows a gradation the scoring of trail-making B test with lowest in the 
patients with schizophrenia followed by the siblings and the controls. In a study by 
Fujiki et al. showed that the relatives of patients with schizophrenia show difference 
in the performance of trail making test. Contrary to the current study, the above said 
study showed a difference in the relatives in the trail-making A test also (168). 
Triads test: 
The triads test was used to measure the divided attention among the subjects. 
This test showed a significant difference between the groups.  When compared with 
the normal control group, the patients with schizophrenia and siblings of patients with 
schizophrenia performed worse. No similar study could be found in the literature 
review using this test. 
  
 98
Working memory: 
In this study, the working memory was measured by N-back tests. These tests 
measured the verbal and visual working memory separately. The results of the current 
study were there was a significant difference between the verbal and visual working 
memory between the groups. In this, the visual working memory showed a greater 
significance of difference between the groups when compared with the verbal 
working memory. In other study, Conklin et al., using the digit forward and digit 
backward method to measure the working memory, showed that there was impairment 
in both the digit forward and backward in the case of patients with schizophrenia 
(169). Conklin et al found out that the first degree relatives of patients with 
schizophrenia had deficits in working memory only when the task at hand required 
much of the reserves of the central executive functions (170). 
Stroop test: 
The stroop test was administered to measure the response inhibition in the 
three different groups. Response inhibition is a sub-test to measure the executive 
functions of the brain. The stroop effect was calculated from the test to measure the 
response inhibition. The mean scores in the three groups were 152.43, 200.8 and 
261.1, for controls, siblings and patients, respectively. There was a significant 
difference between the three groups indicating that the response inhibition was 
affected in the sibling and patient group when compared to the controls. This indicates 
that the sibling group is having deficits in the function of response inhibition when 
compared to the controls. Similar findings were reported by other studies. In a study 
by Jameson et al. which studied the executive functions in the parents and siblings of 
patients with schizophrenia reported a significant difference between the 
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performances of the stroop test when compared with the controls (171). But in a study 
by Becker et al., the post-conflict related performance in stroop test had intact results 
comparable to the general population (172).  
Controlled oral word association test: 
The results from the current study showed that there is a statistical significance 
between the groups in regard to the phonemic fluency. This shows that the word 
production in the patients with schizophrenia is well below the controls. In the case of 
the siblings of patients with schizophrenia, the measurement is significantly different 
from the control group. This shows that there is a deficit in the siblings in the 
phonemic fluency. This is in relation with other studies, Keefe et al., and Dollfus et 
al., which showed that the relatives of patients with schizophrenia performed worse 
when compared with the control group (173-174).  
Animal names test: 
The mean number of new words produced by the control group was 
13.03±1.69, siblings 11.07±1.63 and for the patients with schizophrenia was 
9.13±1.61. There is a statistical difference between the groups. The worse 
performance in the animal names test represents the deficit in the category fluency. 
The patients with schizophrenia have a worse performance in the category fluency. 
Next in line was the siblings of patients with schizophrenia who have a worse 
performance when compared with the control group. These findings corroborate with 
resuts from other studies. Heinrichs and Zakzanis showed that the patients with 
schizophrenia had a low score in the category fluency and executive functioning 
(175). Another study by Laurent et al. showed that the patients with schizophrenia and 
their first degree siblings had impaired verbal fluency when compared with the age 
and sex matched controls (176). 
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Correlation between the P300, neuropsychological test and clinical variables: 
In the current study, there was a significant correlation between the clinical 
variables in the patient with schizophrenia group and the electrophysiological and 
neuropsychological measures. There were significant correlation between the P300 
and the neuropsychological test scores also. The age of onset of illness and the 
duration illness had a significant correlation with the P300 amplitude and latency. 
PANSS positive score did not have a significant correlation with the P300 amplitude 
and latency but PANSS general psychopathology score and total score had a 
significant correlation with them.  
In the neuropsychological tests, digit vigilance test, visual 2-back test and 
stroop test had a significant correlation with the age of onset of illness and the 
duration of illness. They also had a significant correlation with the PANSS general 
psychopathology score and total score. 
When the P300 amplitude and latency were correlated with the 
neuropsychological tests, they showed a significant correlation between the P300 
amplitude an latency in the Cz and Pz electrodes while not much significant 
correlation with the Fz. 
These findings were similar to other studies which have analyzed the 
correlation between P300, neuropsychological tests and symptoms in schizophrenia 
patients (177). Similar studies had shown that there is a reduction in the amplitude of 
the P300 in patients with schizophrenia with significant correlation to the negative 
PANSS scores while there is no significant relation with the PANSS positive  
scores (178). 
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CONCLUSION 
1.  The patients with schizophrenia and their unaffected biological siblings showed 
significant impairments in the event related potential P300 amplitude and 
latency when compared with the controls. 
2.  The patients with schizophrenia and their unaffected biological siblings showed 
significant impairments in the tests administered to measure the 
neuropsychological functioning when compared with the controls. 
3.  Except Trail-making A test and Verbal N-back working memory test, all other 
neuropsychological tests showed impairments in the patient and sibling group 
when compared with the controls. 
4.  Stroop test, Continuous performance test and visual N-back test showed very 
significant differences between the patients with schizophrenia and the 
unaffected biological siblings. 
5.  In patients with schizophrenia, clinical parameters correlated significantly with 
the event related potential P300amlitude and latency.  
6.  Strong correlation is evident between the P300 amplitude and the duration of 
illness and PANSS negative score. 
7.  Age of onset of illness, duration of untreated illness, duration of illness, PANSS 
negative score and PANSS general psychopathology score correlated 
significantly with the neuropsychological tests. Strong correlation is found 
between the stroop and continuous performance test and the clinical variables in 
patients with schizophrenia. 
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LIMITATIONS  
1.  A major limitation in the study was the sample size. A larger sample size would 
have thrown greater light on the analysis and might have revealed clear 
differences between the groups.  
2.  The patients with schizophrenia, at the time of evaluation, were on the 
antipsychotic medications. The presence of these drugs might have an effect on 
the cognitive function of the patients. But it was unethical to withdraw the drug 
during the study period as it can increase the chance of relapse. 
3.  The study was a cross-sectional one measuring the event related potentials and 
neuropsychological performances. This might bring about the individual 
variation the subjects during one assessment. 
4.  Halo effect would have affected the results as the assessor was not blinded to 
subjects from the three different groups.  
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FUTURE DIRECTION 
1.  The patients with schizophrenia could be followed up and periodic assessment 
of the event related potential P300 and neuropsychological tests could be done 
to measure the progress of the illness. This could also be done to see the 
improvement with the medications in the patients. 
2.  The unaffected biological siblings of patients with schizophrenia who have a 
high risk of developing the illness could be followed for early detection of 
symptoms and treatment. This might improve the prognosis of the illness  
3.  Specific cognitive remediation tests could be developed to improve specific 
neuropsychological functions which are very affected in the patients with 
schizophrenia. They could be used as an adjuvant to medications. 
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APPENDIX 
PROFORMA  
Socio-demographic profile: 
Serial number: 
Name: 
Age: 
Sex: 
1. Male 
2. Female 
Education: 
1. Profession or Honours 
 
2.  Graduate or post graduate  
 
3.  Intermediate or post high school diploma  
 
4. High school certificate  
 
5.  Middle school certificate  
 
6.  Primary school certificate  
 
7.  Illiterate 
 
Occupation: 
1.  Profession 
 
2.  Semi-Profession  
 
3.  Clerical, Shop-owner, Farmer  
 
4.  Skilled worker  
 
5.  Semi-skilled worker  
 
6.  Unskilled worker  
 
7.  Unemployed  
Income: 
1.  ≥32050 
 
2. 16020 – 32049 
 
3. 12020 – 16019 
 
4. 8010 – 12019 
 
5. 4810 – 8009 
 
6. 1601 – 4809 
 
7. ≤ 1600 
 
Marital status: 
1. Married  
 
2. Divorcee 
 
3. Single 
 
Socio economic status: 
1. Upper 
2. Upper middle 
3. Lower middle 
4. Upper lower 
5. Lower  
Residence: 
1. Urban 
2. Semi urban 
3. Rural 
 
Type of family: 
1. Joint  
 
2. Nuclear  
Religion: 
1. Hindu 
 
2. Christian 
 
3. Muslim 
 
4. Others   
 
Illness characteristics:   
Age of onset of illness (years): 
Duration of illness (months): 
Lag period for treatment (months): 
Duration of treatment (months): 
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INFORMATION TO PARTICIPANTS 
 
TITLE: ELECTROPHYSIOLOGICAL AND NEUROPSYCHOLOGICAL 
MEASURES IN  
PATIENTS WITH SCHIZOPHRENIA AND THEIR UNAFFECTED BIOLOGICAL 
SIBLINGS:  
A FAMILY STUDY 
Principal Investigator: VIJAYA RAGHAVAN D 
Co-Investigator (if any): 
Name of Participant: 
Site:  MADRAS MEDICAL COLLEGE, CHENNAI 
You are invited to take part in this research/ study/procedures/tests. The information in 
this document is meant to help you decide whether or not to take part. Please feel free to 
ask if you have any queries or concerns. 
What is the purpose of research? 
Schizophrenia is a common disorder characterized by cognitive, social and functional 
impairments. It usually presents as positive symptoms like delusions and 
hallucinations. These symptoms may last for a long time. Early identification of the 
disorder and screening tools for the disorder in the general population will be of 
immense help in finding the vulnerable people and following them up and treating 
them at the earliest. We want to test the efficacy and safety of a new lab tests this 
disease/condition.  
We have obtained permission from the Institutional Ethics Committee.  
The study design 
All patients in the study will be divided into three groups. You will be assigned to 
either of the groups. The three groups will be patients with schizophrenia, unaffected 
biological siblings of patients with schizophrenia and normal controls who have no 
family history of any mental illness.  
Study Procedures 
The study involves evaluation of lab test for which we will be monitoring your EEG 
and neuropsychological tests. The planned scheduled visits involve visits at two days 
in a week initial visit. You will be required to visit the hospital two times during the 
study.  
At each visit, the study physician will examine you. EEG or neuropsychological test 
measures will be collected at each visit. These tests are essential to monitor your 
condition, and to assess the safety and efficacy of the treatment given to you. 
In addition, if you notice any physical or mental change(s), you must contact the 
persons listed at the end  
of the document. You may have to come to the hospital (study site) for examination 
and investigations  
apart from your scheduled visits, if required.  
 
Women of childbearing potential 
You must not participate if you are pregnant, breastfeeding a child, or if you are of 
childbearing potential and not practicing effective methods of contraception (for 
studies/procedures which may harm the fetus).    
Possible risks to you – If any, Briefly mention: In this study, EEG electrode will be 
place in the scalp  
of the participants and the event related potential will recorded, during the placement 
of the electrode gel  
will be used to adhere the leads to the scalp for better conduction. It may rarely cause 
burning sensation  
in the skin, which will subside by itself in few minutes. 
Possible benefits to you - If any, Briefly mention: Since the tests in them has a 
screening potential for the disease, the persons with abnormal scores will be referred 
for appropriate medical services for further evaluation and treatment. 
 Possible benefits to other people  
The results of the research may provide benefits to the society in terms of 
advancement of medical knowledge and/or therapeutic benefit to future patients.  
Confidentiality of the information obtained from you 
You have the right to confidentiality regarding the privacy of your medical 
information (personal details, results of physical examinations, investigations, and 
your medical history). By signing this document, you will be allowing the research 
team investigators, other study personnel, sponsors, Institutional Ethics Committee 
and any person or agency required by law like the Drug Controller General of India to 
view your data, if required. The information from this study, if published in scientific 
journals or presented at scientific meetings, will not reveal your identity. 
How will your decision to not participate in the study affect you? 
Your decision not to participate in this research study will not affect your medical 
care or your relationship with the investigator or the institution. You will be taken 
care of and you will not loose any benefits to which you are entitled.  
Can you decide to stop participating in the study once you start? 
The participation in this research is purely voluntary and you have the right to 
withdraw from this study at any time during the course of the study without giving 
any reasons. However, it is advisable that you talk to the research team prior to 
stopping the treatment/discontinuing of procedures etc. 
 
Signature of Investigator                                                      Signature of Participant   
 
Date:                                                                                                     Date:   
Informed consent form 
 
Title of the study - ELECTROPHYSIOLOGICAL AND 
NEUROPSYCHOLOGICAL MEASURES IN PATIENTS WITH 
SCHIZOPHRENIA AND THEIR UNAFFECTED BIOLOGICAL SIBLINGS: A 
FAMILY STUDY 
Name of the participant: ____________________________________________ 
Name of the Principal/Co-Investigator: VIJAYA RAGHAVAN D 
Name of the Institution: MADRAS MEDICAL COLLEGE, CHENNAI 
Name and address of the sponsor / agency (ie), if any:  
 
I, ________, have read the information in this form (or it has been read to me). I was 
free to ask any questions and they have been answered. I am over 18 years of age and, 
exercising my free power of choice, hereby give my consent to be included as a 
participant in the study titled “ELECTROPHYSIOLOGICAL AND 
NEUROPSYCHOLOGICAL MEASURES IN PATIENTS WITH 
SCHIZOPHRENIA AND THEIR UNAFFECTED BIOLOGICAL SIBLINGS: A 
FAMILY STUDY” 
  
(1) I have read and understood this consent form and the information provided to me. 
(2) I have had the consent document explained to me. 
(3) I have been explained about the nature of the study. 
(4)  I have been explained about my rights and responsibilities by the investigator. 
(5) I have informed the investigator of all the treatments I am taking or have taken in 
the past months/ years including any native (alternative) treatments. 
(6) I have been advised about the risks associated with my participation in the 
study. 
(7) I agree to cooperate with the investigator and I will inform him/her immediately if 
I suffer unusual   symptoms.  
(8) I have not participated in any research study within the past _____ month(s). 
(9) [I have not donated blood within the past _____months -- Add if the study 
involves extensive blood sampling] 
(10) I am aware of the fact that I can opt out of the study at any time without having 
to give any reason and this will not affect my future treatment in the hospital. 
(11) I am also aware that the investigators may terminate my participation in the study 
at any time, for any reason, without my consent. 
(12) I hereby give permission to the investigators to release the information obtained 
from me as result of participation in this study to the sponsors, regulatory authorities, 
Government agencies, and ethics committee. I understand that they may inspect my 
original records. 
(13) I understand that my identity will be kept confidential if my data are publicly 
presented. 
(14) I have had my questions answered to my satisfaction. 
(15) I consent voluntarily to participate as a participant in the research study. 
      
I am aware, that if I have any questions during this study, I should contact the 
investigators. By signing this consent from, I attest that the information given in this 
document has been clearly explained to me and understood by me. I will be given a 
copy of this consent document. 
 
 
 
  
For adult participants 
Name and signature / thumb impression of the participant (or legal representative if 
participant incompetent): 
(Name) __________________________(Signature)___________________ Date: __________   
 
Name and signature of impartial witness (required for illiterate patients):  
(Name) __________________________ (Signature)___________________ Date:__________  
Address and contact number of the impartial witness: _________________________________  
 
Name and signature of the Investigator or his representative obtaining consent: 
(Name) __________________________ (Signature)___________________ (Date)__________ 
 
For children being enrolled in research 
Whether child’s assent was asked: Yes No (Tick one) 
[If the answer to the above question is Yes, write the following phrase: 
You agree with the manner in which assent was asked for from your child and 
given by your child.  
You agree to have your child take part in this study.] 
[If answer to the above question is No, give 
reason(s):___________________________ 
 
Although your child did not or could not give his or her assent, you agree to your 
child’s participation in this study.] 
 
 
 
 
Name and signature / thumb impression of the participant’s parent(s) (or legal 
representative): 
(Name) __________________________ (Signature)______________ Date: __________ 
(Name) __________________________ (Signature)______________ Date: __________ 
 
Name and signature of impartial witness (required if parents of participant child illiterate): 
(Name) __________________________ (Signature)______________ Date:__________  
Address and contact number of the impartial witness: ___________________ 
______________________________________________ 
 
Name and signature of the Investigator or his representative obtaining consent: 
(Name) __________________________ (Signature) _________________ (Date) __________  
 
 
 
 
 
  
ஆராய்ச்சி தகவல் தாள் 
தைலப்பு: ஸ்கிேசாஃப்rனியா ேநாயாளிகள் மற்றும் அவர்களது 
பாதிக்கப்படாத உடன்பிறப்பகளின் மின் உடலியங்கியல் மற்றும் 
நரம்பியஉளவியல் அளவுகள் பற்றிய குடும்ப ஆய்வு. 
ஆராய்ச்சி ெசய்பவrன் ெபயர்: மரு. விஐய ராகவன் .த  
பங்குெகாள்வrன் ெபயர்: 
இடம் : இராஜிவ் காந்தி அரசு ெபாது மருத்துவமைன,  
ெசன்ைன- 600003. 
ஆராய்ச்சியின் ேநாக்கம் :   ஸ்கிேசாஃப்rனியா ேநாயாளிகள் 
மற்றும் அவர்களது பாதிக்கப்படாத உடன்பிறப்பகளின் மின் 
உடலியங்கியல் மற்றும் நரம்பியஉளவியல் அளவுகள் பற்றிய 
குடும்ப ஆய்வு நைடெபறுகிறது. நீங்களும் இந்த ஆராய்ச்சியில் 
பங்ேகற்க விரும்புகிேறாம். 
 முடிவுகைள அல்லது கருத்துக்கைள ெவளியிடும்ேபாேதா 
அல்லது ஆராய்ச்சியின் ேபாேதா தங்களது ெபயைரேயா அல்லது 
அைடயாளங்கைளேயா ெவளியிடமாட்ேடாம் என்பைதயும் 
ெதrவித்துக் ெகாள்கிேறாம். 
 இந்த ஆய்வின் முடிவுகைள ஆராய்ச்சியின்ேபாது அல்லது 
ஆராய்ச்சியின் முடிவின் ேபாது தங்களுக்கு அறிவிக்கப்படும் 
என்பைதயும் ெதrவித்துக் ெகாள்கிேறாம். 
 இந்த ஆராய்ச்சியில் பங்ேகற்பது தங்களுைடய விருப்பத்தின் 
ேபrல் தான் இருக்கிறது. ேமலும் நீங்கள் எந்ேநரமும் இந்த 
ஆராய்ச்சியிலிருந்து பின்வாங்கலாம் என்பைதயும் ெதrவித்துக் 
ெகாள்கிேறாம். 
 
ஆராய்ச்சியாளrன் ைகெயாப்பம்     பங்ேகற்பாளர் ைகெயாப்பம்  
நாள்   :____________ 
இடம் : ____________ 
 
 
ஆராய்ச்சி ஒப்புதல் படிவம் 
ஆராய்ச்சியின் தைலப்பு:  ஸ்கிேசாஃப்rனியா ேநாயாளிகள் மற்றும் 
அவர்களது பாதிக்கப்படாத உடன்பிறப்பகளின் மின் உடலியங்கியல் 
மற்றும் நரம்பியஉளவியல் அளவுகள் பற்றிய குடும்ப ஆய்வு. 
பங்குெகாள்வrன் ெபயர்: 
 
ஆராய்ச்சி ெசய்பவrன் ெபயர்: மரு. விஐய ராகவன் .த    
 
இடம் : இராஜிவ் காந்தி அரசு ெபாது மருத்துவமைன, ெசன்ைன- 600003.  
       _______________________  எனும் நான், எனக்கு ெகாடுக்கப்பட்ட 
தகவல் தாளிைன படித்து புrந்துெகாண்ேடன். நான் 18 வயைத 
கடந்திருப்பதால் என்னுைடய சுய நிைனவுடனும் மற்றும் முழு 
சுதந்திரத்துடனும் இந்த ஆராய்ச்சியில் என்ைனச் ேசர்த்துக்ெகாள்ள 
சம்மதிக்கிேறன். 
நான் எனக்கு ெகாடுக்கப்பட்ட தகவல் தாளிைன படித்து புrந்துெகாண்ேடன். 
எனக்கு இந்த ஆராய்ச்சியின் ஒப்புதல் படிவம் விளக்கப்பட்டது. 
எனக்கு இந்த ஆராய்ச்சியின் ேநாக்கமும், விவரங்களும் விளக்கப்பட்டது. 
எனக்கு என்னுைடய உrைமகைள பற்றி விளக்கப்பட்டது. 
நான் இதுவைர எடுத்துக்ெகாண்ட அைணத்து மருத்துவ முைறகைளப் 
பற்றி ெதrவித்திருக்கிேறன். 
இந்த ஆராய்ச்சியில் இருந்து நான் எந்ேநரமும் பின் வாங்கலாம் 
என்பைதயும் அதனால் எந்த பாதிப்பும் எற்படாது என்பைதயும் நான் 
புrந்துெகாண்ேடன். 
என்ைன பற்றிய எந்த தகவல்களும் அைடயாளமும் ெவளியிடபட 
மாட்டாது என்பைத நான் புrந்துெகாண்ேடன். 
என்னுைடய முழு சுதந்திரத்துடனும் இந்த ஆராய்ச்சியில் என்ைனச் 
ேசர்த்துக்ெகாள்ள சம்மதிக்கிேறன். 
 
  பங்ேகற்பாளர் ைகெயாப்பம்             ஆராய்ச்சியாளrன் ைகெயாப்பம்            
நாள்  :  _________ 
இடம் : __________ 
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1 25 1 8 4 5 4 1 0 1 3 1 11.5 9.2 7.3 348 381 356 375 636 15 55 118 63 5 8 1 7 2 6 3 4 5 8 13 175
2 25 2 10 4 5 4 1 0 3 1 1 11.6 14.3 10.6 330 336 332 275 548 11 41 81 40 4 9 0 8 1 8 1 5 4 9 15 158
3 27 2 8 7 7 4 1 0 1 1 2 8.3 10.1 8.3 364 371 360 358 618 14 58 120 62 4 9 0 7 2 7 2 4 5 7 12 181
4 35 1 9 6 6 4 1 0 1 1 1 10.2 12.4 9.8 362 355 348 298 579 13 51 108 57 5 9 0 8 1 8 1 4 5 7 12 168
5 33 1 8 6 6 4 1 0 1 2 1 6.4 10.9 9.1 349 376 349 335 607 15 56 111 55 6 8 1 8 1 7 2 4 5 6 16 192
6 27 2 9 7 7 5 1 0 2 1 1 10.1 12.8 10.2 351 358 338 318 598 14 49 100 51 5 9 0 8 1 8 1 5 4 8 11 159
7 26 1 12 5 5 4 1 0 1 1 2 15.8 16.6 11.6 295 296 311 193 397 6 23 52 29 2 9 0 9 0 9 0 7 2 12 16 128
8 30 2 8 7 7 4 1 0 1 1 1 8.9 10.2 8.1 369 385 349 368 626 11 58 98 40 6 7 2 8 1 7 2 4 5 9 10 187
9 30 1 12 5 5 4 1 0 1 2 1 16.4 15.6 12.5 302 295 308 218 518 8 25 51 26 1 9 0 8 1 9 0 6 3 11 12 118
10 26 1 9 6 6 4 1 0 1 1 1 11.3 11.3 10.3 308 348 331 288 583 15 46 86 40 5 8 1 8 1 8 1 5 4 7 14 161
11 31 2 8 7 7 4 1 0 1 1 2 9.6 9.9 8.6 352 371 342 317 667 15 53 108 55 5 9 0 7 2 6 3 5 4 7 13 173
12 25 1 12 4 4 3 5 0 2 1 1 14.8 18.6 10.5 299 286 317 234 435 7 27 56 29 2 9 0 8 1 9 0 6 3 12 10 118
13 28 2 10 5 5 4 1 0 1 1 1 12.1 15.3 10.9 319 330 331 281 531 10 43 84 41 3 9 0 8 1 8 1 6 3 9 12 155
14 34 1 8 5 5 4 3 0 1 1 1 8.1 12.1 6.5 348 369 346 358 627 13 49 118 77 5 9 0 8 1 7 2 5 4 6 12 179
15 25 2 11 4 4 4 5 0 3 2 1 13.8 15.6 10.1 318 318 328 251 592 9 38 68 30 3 9 0 8 1 8 1 6 3 10 14 142
16 28 2 9 5 5 4 1 0 1 1 1 10.4 12.2 9.8 368 345 335 309 617 11 46 89 43 4 8 1 8 1 8 1 6 3 8 14 166
17 26 1 8 7 7 5 1 0 2 1 2 7.6 11.5 8.6 337 381 350 363 673 14 58 102 44 5 8 1 7 2 7 2 5 4 8 16 171
18 26 1 11 5 5 4 5 0 1 1 1 11.9 14.9 10.5 326 215 328 238 498 9 29 81 52 2 9 0 8 1 8 1 6 3 12 12 134
19 31 2 10 7 7 4 1 0 1 1 1 12.1 15.1 11.2 334 338 334 279 539 10 38 85 47 3 9 0 8 1 8 1 6 3 10 16 151
20 27 1 12 5 5 4 1 0 2 3 1 17.2 18.3 12.6 312 281 321 191 445 7 24 66 42 1 9 0 8 1 8 1 7 2 11 13 108
21 32 2 9 6 6 4 1 0 1 1 1 10.4 10.6 9.2 352 358 346 289 617 10 47 89 42 5 9 0 8 1 8 1 6 3 7 15 151
22 32 1 13 4 4 3 5 0 1 2 1 19.1 19.3 12.7 285 275 300 179 397 6 20 50 30 1 9 0 9 0 9 0 7 2 13 13 100
23 28 1 9 6 6 4 1 0 2 1 1 10.5 13.1 10.2 318 343 336 317 583 11 48 106 58 4 9 0 8 1 8 1 5 4 7 12 160
24 32 2 13 4 4 3 3 0 3 1 1 18.9 19.6 13.1 289 278 304 174 385 6 21 55 34 1 9 0 8 1 8 1 6 3 12 13 103
25 27 2 10 7 7 5 1 0 1 1 1 11.5 14.8 10.4 325 318 335 271 553 11 40 88 44 4 9 0 8 1 7 2 6 3 9 12 149
26 31 1 9 7 7 4 1 0 2 3 1 9.9 13.1 10.8 329 344 349 329 591 12 49 96 47 5 9 0 8 1 8 1 5 4 6 13 158
27 33 1 11 5 5 4 1 0 1 1 2 13.2 15.6 11.2 317 327 321 248 437 8 30 76 46 3 9 0 8 1 8 1 6 3 9 12 128
28 28 1 8 6 6 4 1 0 1 1 1 9.3 10.5 8.8 376 366 358 363 611 13 60 104 44 5 8 1 7 2 6 3 5 4 5 13 170
29 26 2 10 5 5 4 1 0 1 3 1 11.6 14.6 9.8 330 309 330 274 548 10 41 80 39 3 9 0 8 1 7 2 5 4 8 14 153
30 26 1 9 6 6 4 5 0 1 1 1 10.3 12.8 9.5 365 349 343 334 579 12 46 91 45 6 8 1 8 1 7 2 5 4 8 11 177
31 31 1 8 6 6 4 1 1 1 1 2 4.1 8.3 4.6 364 400 368 369 728 16 55 112 57 9 8 1 6 3 5 4 3 6 5 9 218
32 31 2 13 7 7 5 1 1 2 2 1 12.9 14.7 11.5 328 300 331 223 450 9 35 81 46 2 9 0 9 0 8 1 6 3 11 15 145
33 29 1 9 5 5 4 1 1 1 1 2 7.1 9.2 9.5 351 376 368 325 693 16 49 108 59 8 8 1 8 1 6 3 4 5 6 10 201
34 25 1 13 5 5 4 5 1 1 3 1 13 13.8 12.9 336 418 339 229 468 12 36 86 50 2 9 0 8 1 7 2 5 4 12 13 150
35 27 1 8 6 6 4 5 1 1 1 2 5.6 6.7 6.2 361 398 365 368 704 19 51 118 67 8 8 1 8 1 5 4 3 6 7 9 223
36 25 2 13 3 4 3 5 1 1 1 1 12.4 14.6 11.9 333 426 369 239 495 11 38 82 44 2 9 0 8 1 8 1 6 3 10 14 148
37 29 1 9 6 6 4 1 1 2 1 2 7.2 10.1 9.2 351 376 352 328 675 16 49 106 57 7 9 0 8 1 5 4 5 4 6 11 216
38 30 1 9 7 7 5 1 1 1 1 1 7.6 9.8 9.6 358 381 361 241 688 15 51 102 51 8 9 0 8 1 6 3 4 5 7 11 222
39 32 2 10 7 7 4 1 1 3 3 1 8.4 10.6 10.2 341 342 355 294 618 15 45 98 53 7 9 0 8 1 6 3 4 5 8 12 198
40 32 1 8 6 6 4 1 1 1 1 2 6.8 7.5 8.2 362 376 359 368 728 17 53 111 78 8 9 0 7 2 6 3 3 6 9 10 211
41 25 2 12 4 4 3 1 1 1 1 2 11.5 13.2 11.9 321 318 362 265 498 13 39 91 52 5 9 0 8 1 7 2 5 4 9 13 156
42 26 1 9 5 5 4 1 1 2 2 1 7.1 10.1 8.4 356 368 354 348 698 16 52 106 54 8 8 1 7 2 6 3 3 6 5 11 210
43 25 2 10 6 6 4 1 1 1 1 2 8.4 10.8 9.3 338 346 361 286 609 14 41 101 60 6 9 0 8 1 6 3 4 5 7 12 200
44 26 1 8 7 7 4 1 1 1 1 1 6.3 7.8 7.5 359 369 342 361 714 17 52 114 62 9 7 2 7 2 5 4 3 6 5 9 234
45 29 2 9 7 7 5 1 1 1 1 2 6.9 9.6 9.5 347 366 349 318 706 16 49 99 50 8 8 1 7 2 5 4 3 6 7 10 228
46 29 2 11 7 7 4 1 1 2 1 1 8.9 11.2 10.6 342 332 345 286 567 12 37 88 51 5 9 0 8 1 7 2 4 5 8 12 183
47 29 1 8 6 6 4 1 1 1 1 2 5.4 6.5 5.7 355 301 370 361 735 19 54 120 66 7 7 2 8 1 6 3 3 6 6 10 244
48 31 2 10 7 7 4 1 1 1 1 1 7.9 10.9 9.6 338 342 352 279 600 16 45 100 55 5 9 0 7 2 6 3 5 4 7 12 181
49 25 2 9 6 6 4 1 1 3 1 2 6.3 9.6 8.5 349 347 359 308 675 16 51 110 59 7 9 0 7 2 5 4 3 6 6 11 202
50 33 1 8 6 6 4 1 1 1 1 1 6.7 8.4 8.1 350 327 361 366 718 17 54 109 55 8 9 0 8 1 5 4 4 5 6 9 231
51 25 2 9 6 6 4 3 1 1 3 2 7.9 10.3 9.2 356 361 362 341 651 15 49 101 52 9 8 1 7 2 5 4 4 5 6 10 206
52 35 2 10 6 6 4 1 1 2 1 1 7.9 10.9 9.9 346 336 320 283 589 15 43 96 53 7 9 0 7 2 6 3 5 4 8 11 195
53 26 1 9 5 5 4 5 1 1 2 2 8.4 9.9 8.5 353 376 363 298 661 14 52 98 46 8 9 0 8 1 6 3 4 5 7 9 221
54 26 2 8 5 5 4 1 1 1 1 1 7.1 9.1 7.4 365 323 369 339 702 15 50 111 61 8 9 0 8 1 5 4 3 6 7 10 252
55 34 2 12 7 7 5 1 1 1 1 1 10.4 12.1 10.9 335 315 331 236 492 11 41 83 42 5 9 0 8 1 7 2 6 3 8 13 169
56 27 1 11 4 4 3 1 1 1 1 2 9.8 12.4 10.1 346 330 342 267 516 13 45 89 44 6 9 0 7 2 7 2 6 3 9 12 187
57 33 2 8 7 7 4 1 1 1 1 1 7.6 6.2 4.8 358 345 351 318 703 16 49 106 57 9 8 1 6 3 5 4 3 6 5 10 223
58 26 2 12 4 4 4 1 1 1 1 2 11.4 10.5 11.8 337 308 343 239 507 13 39 85 46 5 9 0 8 1 7 2 5 4 9 13 158
59 29 2 11 7 7 4 1 1 2 2 1 9.5 11.9 10.2 344 345 349 276 521 13 42 93 51 6 9 0 7 2 6 3 5 4 10 12 164
60 27 1 8 5 5 4 1 1 1 1 1 7.2 7.6 9.1 357 362 368 345 729 16 53 118 65 8 9 0 6 3 6 3 3 6 6 9 248
61 25 2 9 7 7 5 1 2 1 1 1 22 36 12 24 20 14 38 72 3.4 6.8 5.9 381 377 382 356 721 20 60 141 81 9 8 1 5 4 5 4 2 7 6 7 273
62 25 1 9 7 7 4 1 2 1 3 2 21 48 24 24 24 18 46 88 4.1 6.1 6.2 392 381 389 361 734 22 63 138 75 10 8 1 4 5 4 5 3 6 5 6 281
63 25 1 8 7 7 4 5 2 2 1 1 18 84 48 36 23 21 69 113 2.5 5.4 3.2 400 392 395 380 765 23 69 150 81 11 7 2 5 4 4 5 3 6 4 7 296
64 26 2 10 7 7 4 1 2 1 1 1 22 48 12 36 14 19 58 91 4.3 7.8 6.8 365 365 370 326 645 17 54 126 72 9 9 0 5 4 5 4 4 5 7 9 251
65 27 1 11 6 6 4 1 2 1 2 1 23 48 12 36 18 31 33 82 4.9 7.6 7.3 352 358 368 307 618 14 50 116 66 7 9 0 6 3 6 3 4 5 7 10 246
66 35 2 8 7 7 4 2 2 2 1 2 19 192 72 120 21 29 68 118 1.6 6.2 1.5 389 383 381 378 751 19 70 148 78 12 7 2 5 4 4 5 2 7 6 7 294
67 33 1 10 7 7 5 3 2 1 1 1 24 108 36 72 21 28 71 120 4.2 8.1 6.6 368 369 378 321 652 18 55 129 74 9 9 0 5 4 5 4 3 6 6 10 250
68 25 1 9 6 6 4 5 2 1 3 1 20 60 24 36 17 18 47 82 2.9 7.5 5.2 388 377 385 366 701 20 59 138 79 9 9 0 6 3 5 4 3 6 5 9 274
69 25 2 10 5 5 4 5 2 1 1 2 21 48 24 24 19 21 56 96 3.6 7.6 6.8 371 351 371 331 667 19 53 118 65 8 8 1 6 3 6 3 3 6 5 11 255
70 26 1 10 5 5 4 5 2 1 1 1 22 48 12 36 15 23 44 82 5.1 7.1 7.5 356 366 364 338 658 17 55 121 66 8 9 0 6 3 6 3 3 6 6 11 248
71 26 1 9 5 5 4 1 2 1 1 1 22 48 24 24 17 11 44 72 4.2 6.9 6.3 378 379 383 357 749 19 59 136 77 10 8 1 6 3 5 4 2 7 5 8 263
72 31 2 8 6 6 4 3 2 1 1 2 18 156 60 96 19 36 58 113 3.3 6.1 3.4 381 393 389 369 753 22 64 149 85 11 8 1 5 4 4 5 2 7 4 8 289
73 34 1 10 6 6 4 4 2 3 2 1 23 132 36 96 22 27 54 103 5.9 7.5 6.7 366 338 361 346 631 19 58 131 73 9 9 0 6 3 6 3 3 6 6 9 259
74 31 1 9 6 6 4 1 2 1 1 1 22 108 36 72 24 35 76 135 4.5 7 5.2 389 361 374 373 676 20 61 146 85 9 9 0 6 3 5 4 2 7 6 10 273
75 26 2 12 7 7 4 5 2 1 1 1 24 24 6 18 16 14 33 63 6.2 9.6 7.7 341 334 355 298 572 14 46 112 66 7 9 0 8 1 6 3 4 5 9 11 218
76 31 1 10 6 6 5 3 2 2 1 2 26 60 12 48 23 24 35 82 5.5 8.4 7.2 356 371 359 375 618 15 51 128 77 8 9 0 7 2 5 4 3 6 7 10 238
77 33 2 9 7 7 4 3 2 1 3 1 27 72 24 48 28 28 43 99 3.7 6.5 6.2 382 386 363 367 691 17 58 136 78 8 8 1 5 4 5 4 2 7 6 9 256
78 26 1 8 7 7 5 1 2 1 1 1 19 84 12 72 18 32 58 108 2.9 5.4 2.5 391 389 392 371 732 26 61 150 89 10 8 1 4 5 4 5 2 7 4 7 273
79 27 2 13 5 5 4 1 2 3 1 1 25 24 8 16 18 18 38 74 6.9 11.5 11.2 330 330 345 280 526 11 40 108 68 4 9 0 8 1 7 2 5 4 8 12 212
80 28 2 8 4 4 3 1 2 1 2 2 23 60 24 36 24 24 43 91 3.7 7.2 4.7 376 398 386 361 727 22 66 141 75 10 8 1 6 3 4 5 2 7 5 8 288
81 32 1 9 7 7 4 2 2 1 1 1 17 180 84 96 23 39 71 133 3.9 6.6 5.7 368 366 371 346 698 20 61 145 84 9 8 1 5 4 5 4 3 6 5 10 263
82 28 2 12 7 7 4 1 2 1 1 1 23 60 24 36 24 34 54 112 5.6 10.5 10.2 346 348 352 302 583 16 47 119 72 6 9 0 7 2 6 3 4 5 7 11 228
83 32 1 8 7 7 4 1 2 3 1 1 21 132 36 96 24 38 68 130 2.8 3.5 4.3 396 400 376 378 734 19 59 149 90 12 7 2 4 5 5 4 3 6 5 8 251
84 29 2 11 4 4 3 1 2 1 1 2 23 72 36 36 31 14 33 78 5.1 7.9 6.8 355 351 368 313 619 18 46 122 76 8 9 0 6 3 6 3 4 5 7 9 223
85 27 1 9 6 6 4 1 2 1 2 1 22 60 24 36 22 21 48 91 4.3 5.4 5.1 384 369 372 341 678 19 58 138 80 9 9 0 5 4 6 3 3 6 5 12 276
86 30 1 13 4 4 3 5 2 2 1 2 23 84 48 36 23 24 59 106 6.6 10.5 10.5 330 332 349 291 553 11 42 103 61 6 9 0 8 1 6 3 4 5 9 10 233
87 30 2 9 7 7 5 1 2 1 3 1 21 108 24 84 21 32 68 121 2.7 4.5 6.3 375 355 384 368 708 19 55 134 79 10 8 1 5 4 5 4 3 6 5 7 266
88 27 1 8 6 6 5 5 2 1 1 2 22 60 36 24 23 14 46 83 1.9 2.8 5.9 388 371 383 373 725 22 61 138 77 11 7 2 5 4 5 4 2 7 4 8 281
89 32 1 8 6 6 4 1 2 1 1 1 19 156 72 84 14 39 75 128 3.4 3.9 6.1 376 386 386 368 701 20 62 145 83 12 7 2 5 4 4 5 2 7 4 10 298
90 27 2 9 7 7 5 1 2 2 2 2 23 48 12 36 18 21 42 81 4.2 7.5 6.8 392 368 379 333 673 19 62 137 75 10 8 1 4 5 5 4 3 6 4 10 277
